0001493152-21-011799.txt : 20210517 0001493152-21-011799.hdr.sgml : 20210517 20210517153324 ACCESSION NUMBER: 0001493152-21-011799 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210517 DATE AS OF CHANGE: 20210517 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Protagenic Therapeutics, Inc.\new CENTRAL INDEX KEY: 0001022899 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 061390025 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12555 FILM NUMBER: 21929895 BUSINESS ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: (212) 994-8200 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: Atrinsic, Inc. DATE OF NAME CHANGE: 20090630 FORMER COMPANY: FORMER CONFORMED NAME: NEW MOTION, INC. DATE OF NAME CHANGE: 20070504 FORMER COMPANY: FORMER CONFORMED NAME: MPLC, Inc. DATE OF NAME CHANGE: 20050608 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X]	Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2021

[ ]	Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from _________to___________

Commission File Number: 000-51353

PROTAGENIC THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		06-1390025
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

149 Fifth Avenue, Suite 500, New York, New York 10010

(Address of Principal Executive Office) (Zip Code)

(212) 994-8200

Registrant’s Telephone Number Including Area Code

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Ticker symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001	PTIX	Nasdaq Capital Market
Common Stock Purchase Warrant	PTIXW	Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[ ]	Accelerated filer	[ ]
Non-accelerated filer	[X]	Smaller reporting company	[X]
Emerging Growth Company	[ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 126-2 of the Exchange Act).

[ ] Yes [X] No

As of May 14, 2021 there were 14,643,780 shares of common stock outstanding.

PROTAGENIC THERAPEUTICS, INC.

Form 10-Q Report

For the Fiscal Quarter Ended March 31, 2021

TABLE OF CONTENTS

		Page
Part I.	Financial Information

Item 1	Financial Statements:

	Consolidated Balance Sheets at March 31, 2021 (unaudited) and December 31, 2020	3

	Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2021 and 2020 (unaudited)	4

	Consolidated Statements of Changes in Stockholders’ Deficit for the three months ended March 31, 2021 and 2020 (unaudited)	5

	Consolidated Statements of Cash Flows for three months ended March 31, 2021 and 2020 (unaudited)	6

	Notes to Consolidated Financial Statements (unaudited)	7

Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18

Item 3	Quantitative and Qualitative Disclosures about Market Risk	19

Item 4	Controls and Procedures	19

Part II.	Other Information

Item 1	Legal Proceedings	20

Item 1A	Risk Factors	20

Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	20

Item 3	Defaults upon Senior Securities	21

Item 4	Mine Safety Disclosures	21

Item 5	Other Information	21

Item 6	Exhibits	21

Signatures		22

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

PROTAGENIC THERAPEUTICS, INC., AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

(Unaudited)

	March 31,			December 31,
	2021			2020
ASSETS

CURRENT ASSETS

Cash	$	191,674		$	671,091
Prepaid expenses		4,468			208,156

TOTAL CURRENT ASSETS		196,142			879,247

TOTAL ASSETS	$	196,142		$	879,247

LIABILITIES AND STOCKHOLDERS’ DEFICIT

CURRENT LIABILITIES

Accounts payable and accrued expenses	$	650,968		$	571,517
Derivative liability		-			83,670

TOTAL CURRENT LIABILITIES		650,968			655,187

Note Payable		100,000			-
PIK convertible notes payable, net of debt discount		1,126,048			1,081,384
PIK convertible notes payable, net of debt discount - related parties		301,723			292,412

TOTAL LIABILITIES		2,178,739			2,028,983

STOCKHOLDERS’ DEFICIT
Preferred stock, $0.000001 par value; 20,000,000 shares authorized; 872,766 shares issued and outstanding in the following classes:
Preferred stock; par value $0.000001; 2,000,000 shares authorized; none issued and outstanding		-			-
Series B convertible preferred stock, $0.000001 par value; 18,000,000 shares authorized;
872,766 shares issued and outstanding at March 31, 2021, and December 31, 2020		1			1
Common stock, $.0001 par value, 100,000,000 shares authorized, 10,610,603 and 10,360,480 shares issued and outstanding at March 31, 2021, and December 31, 2020		1,061			1,036
Additional paid-in-capital		17,092,824			16,719,749
Accumulated deficit		(18,905,388	)		(17,698,936	)
Accumulated other comprehensive loss		(171,095	)		(171,586	)

TOTAL STOCKHOLDERS’ DEFICIT		(1,982,597	)		(1,149,736	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	196,142		$	879,247

See accompanying notes to the unaudited consolidated financial statements

PROTAGENIC THERAPEUTICS, INC., AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

	For the three months ended March 31,
	2021			2020
OPERATING AND ADMINISTRATIVE EXPENSES
Research and development		592,351			65,959
General and administrative		613,839			454,777

TOTAL OPERATING AND ADMINISTRATIVE EXPENSES		1,206,190			520,736

LOSS FROM OPERATIONS		(1,206,190	)		(520,736	)

OTHER (EXPENSE) INCOME

Interest income		5			384
Interest expense		(83,937	)		(38,986	)
Change in fair value of derivative liability		83,670			60,749

TOTAL OTHER INCOME (EXPENSES)		(262	)		22,147

LOSS BEFORE INCOME TAX		(1,206,452	)		(498,589	)

INCOME TAX EXPENSE		-			-

NET LOSS	$	(1,206,452	)	$	(498,589	)

COMPREHENSIVE LOSS

Other Comprehensive Loss - net of tax
Foreign exchange translation gain (loss)		491			(2,419	)

TOTAL COMPREHENSIVE LOSS	$	(1,205,961	)	$	(501,008	)

Net loss per common share - Basic and Diluted	$	(0.11	)	$	(0.05	)

Weighted average common shares - Basic and Diluted		10,520,484			10,261,419

See accompanying notes to the unaudited consolidated financial statements

PROTAGENIC THERAPEUTICS, INC., AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

For the Three Months Ended March 31, 2021 and 2020

(Unaudited)

	Series B Convertible								Additional						Accumulated Other
	Preferred Stock				Common Stock				Paid-in-			Accumulated			Comprehensive			Stockholders’
	Shares		Amount		Shares		Amount		Capital			Deficit			Loss			Deficit

For the three months ended March 31, 2020

BALANCE -December 31, 2019		872,766	$	1		10,261,419	$	1,026	$	14,687,172		$	(15,150,201	)	$	(172,364	)	$	(634,366	)

Foreign currency translation loss		-		-		-		-		-			-			(2,419	)		(2,419	)
Stock compensation - stock options		-		-		-		-		360,436			-			-			360,436
Debt discount from beneficial conversion feature		-		-		-		-		89,204			-			-			89,204
Issuance of options for settlement of accrued payroll		-		-		-		-		93,950			-			-			93,950
Modification of warrants		-		-		-		-		5,861			-			-			5,861

Net loss		-		-		-		-		-			(498,589	)		-			(498,589	)

BALANCE -March 31, 2020		872,766	$	1		10,261,419	$	1,026	$	15,236,623		$	(15,648,790	)	$	(174,783	)	$	(585,923	)

For the three months ended March 31, 2021

BALANCE -December 31, 2020		872,766	$	1		10,360,480	$	1,036	$	16,719,749		$	(17,698,936	)	$	(171,586	)	$	(1,149,736	)

Foreign currency translation loss		-		-		-		-		-			-			491			491
Stock compensation - stock options		-		-		-		-		345,975			-			-			345,975
Exercise of options		-		-		10,000		1		(1	)		-			-			-
Exercise of warrants		-		-		240,123		24		27,101			-			-			27,125

Net loss		-		-		-		-		-			(1,206,452	)		-			(1,206,452	)

BALANCE -March 31, 2021		872,766	$	1		10,610,603	$	1,061	$	17,092,824		$	(18,905,388	)	$	(171,095	)	$	(1,982,597	)

See accompanying notes to the unaudited consolidated financial statements

PROTAGENIC THERAPEUTICS, INC., AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the three months ended March 31,
	2021			2020

CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$	(1,206,452	)	$	(498,589	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense		-			84
Stock based compensation		345,975			360,436
Change in fair value of the derivative liability		(83,670	)		(60,749	)
Amortization of debt discount		53,975			27,357
Loss on settlement of accounts payable		-			5,861
Changes in operating assets and liabilities
Prepaid expenses		203,688			11,669
Accounts payable and accrued expenses		78,777			(210,475	)

NET CASH USED IN OPERATING ACTIVITIES		(607,707	)		(364,406	)

CASH FLOWS FROM FINANCING ACTIVITIES

Exercise of warrants for cash		27,125			-
Proceeds from notes payable		100,000			-
Proceeds from convertible notes		-			330,000

NET CASH PROVIDED BY FINANCING ACTIVITIES		127,125			330,000

Effect of exchange rate on cash		1,165			(10,245	)

NET DECREASE IN CASH		(479,417	)		(44,651	)

CASH, BEGINNING OF YEAR		671,091			798,623

CASH, END OF YEAR	$	191,674		$	753,972

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest expense	$	-		$	-
Cash paid for income taxes	$	-		$	-

NONCASH FINANCING AND INVESTING TRANSACTIONS
Debt discount from beneficial conversion feature	$	-		$	89,204
Issuance of options for settlement of accounts payable	$	-		$	93,950

See accompanying notes to the unaudited consolidated financial statements

PROTAGENIC THERAPEUTICS, INC & SUBSIDIARY

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

March 31, 2021

NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS

Company Background

Protagenic Therapeutics, Inc. (“we,” “our,” “Protagenic” or “the Company”), is a Delaware corporation with one subsidiary named Protagenic Therapeutics Canada (2006) Inc. (“PTI Canada”), a corporation formed in 2006 under the laws of the Province of Ontario, Canada.

The Company was previously known as Atrinsic, Inc., a company that was once a reporting company under the Securities Exchange Act of 1934, but that, in 2012 and 2013, reorganized under Chapter 11 of the United States Bankruptcy Code and emerged from bankruptcy. On February 12, 2016, the Company acquired Protagenic Therapeutics, Inc. (“Prior Protagenic”) through a reverse merger.

On February 12, 2016, Protagenic Acquisition Corp., a wholly-owned subsidiary of the Company, merged (the “Merger”) with and into Prior Protagenic. Prior Protagenic was the surviving corporation of the Merger. As a result of the Merger, the Company acquired the business of Prior Protagenic and has continued the existing business operations of Prior Protagenic as a wholly-owned subsidiary. On June 17, 2016, Prior Protagenic merged with and into the Company with the Company as the surviving corporation in the merger. Immediately thereafter, the Company changed its name from Atrinsic, Inc. to Protagenic Therapeutics, Inc.

NOTE 2 - LIQUIDITY

As shown in the accompanying consolidated financial statements, the Company has incurred significant recurring losses resulting in an accumulated deficit. The Company anticipates further losses in the development of its business. The Company had negative cash flows used in operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

Based on its cash resources as of March 31, 2021, the Company has sufficient resources to fund its operations only through May 2021. However, based on cash resources that it received in April 2021 as a consequence of an equity offering, together with its current forecast and budget, management believes that its cash resources will be sufficient to fund its operations at least until the end of the third quarter of 2023. Absent generation of sufficient revenue from the execution of the Company’s business plan and sales revenue is not anticipated before 2024, the Company will need to obtain debt or equity financing by the third quarter of 2023. Because of these factors, the Company believes that this alleviates the substantial doubt in connection with the Company’s ability to continue as a going concern.

NOTE 3 - SUMMARY OF SIGNFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC” for interim financial information. In the opinion of the Company’s management, the accompanying consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended March 31, 2021 and 2020. Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”).

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s financial statements for the year ended December 31, 2020, which contain the audited financial statements and notes thereto, for the years ended December 31, 2020 and 2019 included within the Company’s Form 10-K filed with the SEC on March 25, 2021. The interim results for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.

Principles of consolidation

The condensed consolidated financial statements include the accounts of Protagenic Therapeutics, Inc., and its wholly owned Canadian subsidiary, PTI Canada. All significant intercompany balances and transactions have been eliminated in the condensed consolidated financial statements.

Reclassifications:

Reclassifications of prior periods have been made to conform with current year presentation

Use of estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the condensed consolidated financial statements include income tax provisions, valuation of stock options and warrants and assessment of deferred tax asset valuation allowance.

Concentrations of Credit Risk

The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of March 31, 2021 and December 31, 2020, the Company did not have any cash equivalents.

Fair Value Measurements

ASC 820, “Fair Value Measurements and Disclosure,” defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).

The three levels are described below:

Level 1 Inputs – Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company;

Level 2 Inputs – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;

Level 3 Inputs – Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.

The carrying amount of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair value because of the short term maturity of those instruments. The carrying value of long-term debt approximates fair value since the related rates of interest approximate current market rates.

Transactions involving related parties cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm’s-length transactions unless such representations can be substantiated.

The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of March 31, 2021.

Carrying

Fair Value Measurement Using

Value

Level 1

Level 2

Level 3

Total

Derivative warrants liabilities

—

The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2020.

	Carrying		Fair Value Measurement Using
	Value		Level 1		Level 2		Level 3		Total

Derivative warrants liabilities	$	83,670	$	—	$	—	$	83,670	$	83,670

The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2021 and the year ended December 31, 2020:

	Fair Value Measurement Using Level 3
	Inputs Total
Balance, December 31, 2020	$	83,670
Change in fair value of derivative warrants liabilities		(83,670	)
Balance, March 31, 2021	$	-

The fair value of the derivative feature of the 127,346 and 295,945 warrants issued to the placement agent of the Company’s 2016 private offering (the “2016 Offering”) and to a holder of its debt for debt cancellation in connection with the Merger, respectively on the issuance dates and at the balance sheet dates were calculated using a Black-Scholes option model valued with the following assumptions:

	December 31, 2020
Exercise price		1.25
Risk free interest rate		0.09	%
Dividend yield		0.00	%
Expected volatility		169	%
Contractual term		0.14 Years

Risk-free interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note with a similar expected term on the date of measurement.

Dividend yield: The Company uses a 0% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring dividends in the near future.

Volatility: The Company calculates the expected volatility of the stock price based on the corresponding volatility of the Company’s peer group stock price for a period consistent with the warrants’ expected term.

Expected term: The Company’s expected term is based on the remaining contractual maturity of the warrants.

During the three months ended March 31, 2021 and 2020, the Company marked the derivative feature of the warrants to fair value and recorded a gain of $83,670 and a gain of $60,749 relating to the change in fair value, respectively. The warrants expired on February 21, 2021, resulting in the elimination of the derivative liability.

Derivative Liability

The Company evaluates its options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815-10-05-4 and 815-40-25. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as either an asset or a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the condensed consolidated statements of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation and then the related fair value is reclassified to equity.

The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.

Stock-Based Compensation

The Company accounts for stock based compensation costs under the provisions of ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense related to the fair value of stock based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock based payments granted to employees, officers, non-employees, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC. 718 is also applied to awards modified, repurchased, or canceled during the periods reported.

If any award granted under the Company’s 2016 Equity Compensation Plan (the “2016 Plan”) payable in shares of common stock is forfeited, cancelled, or returned for failure to satisfy vesting requirements, otherwise terminates without payment being made, or if shares of common stock are withheld to cover withholding taxes on options or other awards, the number of shares of common stock as to which such option or award was forfeited, or which were withheld, will be available for future grants under the 2016 Plan. The Company recognizes the impact of forfeitures when they occur.

Basic and Diluted Net (Loss) per Common Share

Basic (loss) per common share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the condensed consolidated statements of operations.

	Potentially Outstanding Dilutive Common Shares
	For the Three Months Ended March 31, 2021		For the Three Months Ended March 31, 2020

Conversion Feature Shares

Common shares issuable under the conversion feature of preferred shares		872,766		872,766

Stock Options		5,673,861		3,925,682

Warrants		3,483,767		3,826,658

Convertible Notes		1,598,000		800,000

Total potentially outstanding dilutive common shares		11,628,394		9,425,106

Research and Development

Research and development expenses are charged to operations as incurred.

Foreign Currency Translation

The Company follows Section 830-10-45 of the FASB Accounting Standards Codification (“Section 830-10-45”) for foreign currency translation to translate the financial statements of the foreign subsidiary from the functional currency, generally the local currency, into U.S. Dollars. Section 830-10-45 sets out the guidance relating to how a reporting entity determines the functional currency of a foreign entity (including of a foreign entity in a highly inflationary economy), re-measures the books of record (if necessary), and characterizes transaction gains and losses. Pursuant to Section 830-10-45, the assets, liabilities, and operations of a foreign entity shall be measured using the functional currency of that entity. An entity’s functional currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the environment, or local currency, in which an entity primarily generates and expends cash.

The functional currency of each foreign subsidiary is determined based on management’s judgment and involves consideration of all relevant economic facts and circumstances affecting the subsidiary. Generally, the currency in which the subsidiary transacts a majority of its transactions, including billings, financing, payroll and other expenditures, would be considered the functional currency, but any dependency upon the parent and the nature of the subsidiary’s operations must also be considered. If a subsidiary’s functional currency is deemed to be the local currency, then any gain or loss associated with the translation of that subsidiary’s financial statements is included in accumulated other comprehensive income. However, if the functional currency is deemed to be the U.S. Dollar, then any gain or loss associated with the re-measurement of these financial statements from the local currency to the functional currency would be included in the condensed consolidated statements of operations and comprehensive income (loss). If the Company disposes of foreign subsidiaries, then any cumulative translation gains or losses would be recorded into the condensed consolidated statements of operations and comprehensive income (loss). If the Company determines that there has been a change in the functional currency of a subsidiary to the U.S. Dollar, any translation gains or losses arising after the date of change would be included within the condensed consolidated statements of operations and comprehensive income (loss).

Based on an assessment of the factors discussed above, the management of the Company determined its subsidiary’s local currency (i.e. the Canadian dollar) to be the functional currency for its foreign subsidiary.

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

NOTE 4 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consist of the following at:

	March 31, 2021		December 31, 2020

Accounting	$	36,161	$	36,161
Research and development		381,062		393,496
Other		233,745		141,860

Total	$	650,968	$	571,517

On October 1, 2019, the Company entered into an agreement with a consultant for toxicology studies. The consultant quoted a commitment of approximately $988,000 as an estimate for the study. 50% of the total price was paid upon the signing of the agreement, 35% of the total price is to be paid upon completion of the in-life study, and the remaining 15% of the total price is to be paid upon the issuance of the report. If the Company cancels the study the Company will be required to pay a cancelation fee. If the cancelation happens prior to the arrival of the test animals then the Company will need to pay between 20% and 50% of the animal fees depending on when the cancellation happens. If the cancellation occurs after the animals arrive but before the study begins then the Company will be responsible for paying 50% of the protocol price plus a fee of $7,000 per room/week for animal husbandry until the animals can be relocated or disposed of. If the Company cancels the study after it has begun then the Company will need to pay any fees for procured items for the study and any nonrecoverable expenses incurred by the consultant. As of March 31, 2021 and December 31, 2020, the Company has paid $174,106 and $174,106 to the consultant and there is a balance of $319,799 and $319,799 due, respectively.

NOTE 5 – NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES)

Note Payable

On March 1, 2021, the Company entered into a $100,000 promissory note. This note is due on February 28, 2026 and accrues interest at a rate of 5% per annum or 7.5% per annum in the case of default. In the event that the Company completes a financing of no less than $7.5 million, then the note holder will be issued warrants valued at $25,000 with an exercise price equal to 110% of the offering cost of the common stock in the financing. These warrants will have a term of five years.

As of March 31, 2021 and December 31, 2020, the Company owes $100,000 and $0 on the outstanding Note, respectively.

Convertible Notes Payable

During the three months ended March 31, 2021 and 2020, the Company amortized $44,664 and $17,943 of the debt discount, respectively. At March 31, 2021 and December 31, 2020, the Company had an unamortized debt discount of $471,452 and $516,116, respectively.

As of March 31, 2021 and December 31, 2020, the Company owes $1,597,500 and $1,597,500 on the outstanding Convertible Notes, respectively.

Maturity Date of Notes for Twelve Months Ending March 31, 2021,	Amount due
2022	$	-
2023		-
2024		1,597,500
2025		-
2026		100,000
Total	$	1,697,500

Convertible Notes Payable – Related Parties

During the three months ended March 31, 2021 and 2020, the Company amortized $9,311 and $9,414 of the debt discount, respectively. At March 31, 2021 and December 31, 2020, the Company had an unamortized debt discount of $98,277 and $107,588, respectively.

As of March 31, 2021 and December 31, 2020, the Company owes $400,000 and $400,000 on the outstanding Convertible Notes, respectively.

Maturity Date of Notes for Twelve Months Ending March 31, 2021,	Amount due
2022	$	-
2023		-
2024		400,000
2025		-
2026		-
Total	$	400,000

NOTE 6 - STOCKHOLDERS’ DEFICIT

Stock-Based Compensation

In connection with the consummation of the Merger completed on February 12, 2016, we adopted Prior Protagenic’s 2006 Employee, Director and Consultant Stock Plan (the “2006 Plan”). On June 17, 2016, our stockholders adopted the 2016 Plan and, as a result, we terminated the 2006 Plan. We will not grant any further awards under the 2006 Plan. All outstanding grants under the 2006 Plan will continue in effect in accordance with the terms of the particular grant and the 2006 Plan.

Pursuant to the 2016 Plan, the Company’s Compensation Committee may grant awards to any employee, officer, director, consultant, advisor or other individual service provider of the Company or any subsidiary. On each of January 1, 2017, January 1, 2019 and January 1, 2020, pursuant to an annual “evergreen” provision contained in the 2016 Plan, the number of shares reserved for future grants was increased by 564,378 shares, or a total of 1,693,134 shares. As a result of these increases, as of March 31, 2021 and December 31, 2020, the aggregate number of shares of common stock available for awards under the 2016 Plan was 4,868,623 shares and 4,868,623 shares, respectively. Options issued under the 2016 Plan are exercisable for up to ten years from the date of issuance.

There were 5,673,861 options outstanding as of March 31, 2021. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows:

Exercise price	$	5.60
Expected dividend yield		0	%
Risk free interest rate		0.81%-1.54 %
Expected life in years		5-10
Expected volatility		149%-158 %

There were 5,597,861 options outstanding as of December 31, 2020. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows:

Exercise price	$	1.75
Expected dividend yield		0	%
Risk free interest rate		0.64%-1.61 %
Expected life in years		10
Expected volatility		140%-146 %

The following is an analysis of the stock option grant activity under the Plan:

				Weighted Average		Weighted Average
	Number			Exercise Price		Remaining Life
Stock Options

Outstanding December 31, 2020		5,597,861		$	1.47		6.48
Granted		366,000		$	5.60		9.69
Expired		(280,000	)	$	1.00		-
Exercised		(10,000	)	$	1.00		-
Outstanding March 31, 2021		5,673,861		$	1.76		6.78

A summary of the status of the Company’s nonvested options as of March 31, 2021, and changes during the three months ended March 31, 2021, is presented below:

Nonvested Options	Options			Weighted- Average Exercise Price
Nonvested at December 31, 2020		862,833		$	1.75
Granted		366,000		$	5.60
Vested		(106,291	)	$	4.70
Forfeited		-		$	-
Nonvested at March 31, 2021		1,122,542		$	2.93

As of March 31, 2021, the Company had 5,673,861 shares issuable under options outstanding at a weighted average exercise price of $1.76 and an intrinsic value of $23,025,089.

The total number of options granted during the three months ended March 31, 2021 and 2020 was 366,000 and 1,387,497, respectively. The exercise price for these options was $5.60 per share.

The Company recognized compensation expense related to options issued of $345,975 and $360,436 during the three months ended March 31, 2021 and 2020, respectively, in which $344,499 and $325,794 is included in general and administrative expenses and $1,476 and $34,641 in research and development expenses, respectively. For the three months ended March 31, 2021, $136,203 of the stock compensation was related to employees and $209,772 was related to non-employees.

As of March 31, 2021, the unamortized stock option expense was $2,778,726 with $397,760 being related to employees and $2,380,966 being related to non-employees. As of March 31, 2021, the weighted average period for the unamortized stock compensation to be recognized is 3.50 years.

On February 25, 2021, the Company issued a total of 366,000 options to purchase shares of the Company’s common stock to five individuals, with 350,000 of these options being issued to related parties. These options had a grant date fair value of $2,009,063. These options have an exercise price of $5.60. 16,000 of the options vest immediately and 350,000 of the options vest monthly over 48 months. These options were approved by the board of directors on February 25, 2021.

During the three months ended March 31, 2021, 10,000 options were exercised for 10,000 shares of the Company’s common stock. These options had an exercise price of $1.00.

Warrants:

A summary of warrant issuances are as follows:

				Weighted Average		Weighted Average
	Number			Exercise Price		Remaining Life
Warrants

Outstanding December 31, 2020		4,007,058		$	1.06		1.86
Expired		(150,249	)		1.25		-
Exercised		(373,042	)		1.25		-
Outstanding March 31, 2021		3,483,767		$	1.03		1.85

As of March 31, 2021, the Company had 3,483,767 shares issuable under warrants outstanding at a weighted average exercise price of $1.03 and an intrinsic value of $16,684,157.

During the three months ended March 31, 2021, 373,042 warrants were exercised for 240,123 shares of the Company’s common stock. The Company received $27,125 from these exercises.

NOTE 7 - COLLABORATIVE AGREEMENTS

The Company and the University of Toronto (the “University”) entered into an agreement effective April 1, 2014 (the “New Research Agreement”) for the performance of a research project titled “Teneurin C-terminal Associated Peptide (“TCAP”) mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism” (the “New Project”). The New Project is to perform research related to work done by Dr. David A. Lovejoy, a professor at the University and stockholder of the Company, in regard to TCAP mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism. In addition to the New Research Agreement, Dr. Lovejoy entered into an agreement with the University in order to commercialize certain technologies. The New Research Agreement expired on March 30, 2016. In February 2017, the New Research Agreement was extended to December 31, 2017. The extension allowed for further development of the technologies and use of their applications. On April 10, 2018, the agreement was amended and the research agreement has been further extended to December 31, 2023.

Prior to January 1, 2016, the University has been granted 25,000 stock options which are fully vested at the exercise price of $1.00 exercisable over a ten year period which ends on April 1, 2022. As of March 31, 2021, Dr. David Lovejoy of the University has been granted 553,299 stock options, of which 431,112 are fully vested and 100,000 have expired. These have an exercise price of $1.00, $1.25 or 1.75 and are exercisable over ten or thirteen year periods which end either on March 30, 2021, December 1, 2022, April 15, 2026, March 1, 2027, October 16, 2027 or on February 13, 2030.

The sponsorship research and development expenses pertaining to the Research Agreements were $0 and $0 for the three months ended March 31, 2021 and 2020, respectively.

NOTE 8 - COMMITMENTS AND CONTINGENCIES

Licensing Agreements

On July 31, 2005, the Company had entered into a Technology License Agreement (“License Agreement”) with the University pursuant to which the University agreed to license to the Company patent rights and other intellectual property, among other things (the “Technologies”). The Technology License Agreement was amended on February 18, 2015 and currently does not provide for an expiration date.

Pursuant to the License Agreement and its amendment, the Company obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement and amendment. In consideration, the Company agreed to pay to the University a royalty payment of 2.5% of net sales of any product based on the Technologies. If the Company elects to sublicense any rights under the License Agreement and amendment, the Company agrees to pay to the University 10% of any up-front sub-license fees for any sub-licenses that occurred on or after September 9, 2006, and, on behalf of the sub-licensee, 2.5% of net sales by the sub-licensee of all products based on the Technologies. The Company had no sales revenue for the three months ended March 31, 2021 and 2020 and therefore was not subject to paying any royalties.

In the event the Company fails to provide the University with semi-annual reports on the progress or fails to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, the University may convert our exclusive license into a non-exclusive arrangement. Interest on any amounts owed under the License Agreement and amendment will be at 3% per annum. All intellectual property rights resulting from the Technologies or improvements thereon will remain the property of the other inventors and/or Dr. Lovejoy, and/or the University, as the case may be. The Company has agreed to pay all out-of- pocket filing, prosecution and maintenance expenses in connection with any patents relating to the Technologies. In the case of infringement upon any patents relating to the Technologies, the Company may elect, at its own expense, to bring a cause of action asserting such infringement. In such a case, after deducting any legal expenses the Company may incur, any settlement proceeds will be subject to the 2.5% royalty payment owed to the University under the License Agreement and amendment.

The patent applications were made in the name of Dr. Lovejoy and other inventors, but the Company’s exclusive, worldwide rights to such patent applications are included in the License Agreement and its amendment with the University. The Company maintains exclusive licensing agreements and it currently controls the five intellectual patent properties.

Legal Proceedings

From time to time we may be named in claims arising in the ordinary course of business. Currently, no legal proceedings, government actions, administrative actions, investigations or claims are pending against us or involve us that, in the opinion of our management, could reasonably be expected to have a material adverse effect on our business and financial condition.

NOTE 9 – RELATED PARTY TRANSACTIONS

The Company is provided free office space consisting of a conference room by the Company Executive Chairman, Dr. Armen. The Company does not pay any rent for the use of this space. This space is used for quarterly board meetings and our annual shareholder meeting.

On February 25, 2021, the Company issued 366,000 options to purchase common stock to 5 individuals, with 350,000 of those options going to related parties. These options had an exercise price of $5.60 and a term of 5 or 10 years. (See Note 6)

NOTE 10- SUBSEQUENT EVENTS

Subsequent to the period, the Company issued 493,177 shares of the Company’s common stock for the net exercise of 695,137 warrants. 231,277 of these shares of common stock were issued to a related party.

Subsequent to the period, the Company issued 360,000 shares of the Company’s common stock for the exercise of 360,000 options. The Company received proceeds of $532,500 from the exercise.

On April, 29, 2021, the Company completed a public offering (“the Offering”) to sell aggregate of 3,180,000 shares of the Company’s common stock together with warrants to purchase an aggregate of 3,180,000 shares of common stock. The Company also granted the underwriters a 45-day option to purchase up to an additional 477,000 shares of Common Stock (the “Option Shares”) and/or warrants to purchase an aggregate of 477,000 shares of Common Stock at the same price. Net proceeds from the Offering were approximately $11.4 million (excluding any sale of the Option Shares), after deducting underwriting discounts and commissions and public offering expenses payable by the Company.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q and other written and oral statements we make from time to time contain certain “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). You can identify these forward-looking statements by the fact they use words such as “could,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” “will,” “potential,” “opportunity,” “future” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. You can also identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes to differ materially from current expectations. These statements relate to, among other things, our business strategy, our research and development, our product development efforts, our ability to commercialize our product candidates, the activities of our licensees, our prospects for initiating partnerships or collaborations, the timing of the introduction of products, the effect of new accounting pronouncements, uncertainty regarding our future operating results and our profitability, anticipated sources of funds as well as our plans, objectives, expectations, and intentions.

We have included more detailed descriptions of these risks and uncertainties and other risks and uncertainties applicable to our business that we believe could cause actual results to differ materially from any forward-looking statements in Part II-Item 1A “Risk Factors” of this Quarterly Report on Form 10-Q. We encourage you to read those descriptions carefully. Although we believe we have been prudent in our plans and assumptions, no assurance can be given that any goal or plan set forth in forward-looking statements can be achieved. We caution investors not to place significant reliance on forward-looking statements contained in this document; such statements need to be evaluated in light of all the information contained in this document. Furthermore, the statements speak only as of the date of this document, and we undertake no obligation to update or revise these statements.

The discussion and analysis of our financial condition and results of operations are based on our financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base these estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We expect to continue to incur significant expenses and minimal positive net cash flows from operations or negative net cash flows from operations for the foreseeable future, and those expenses and losses may fluctuate significantly from quarter-to-quarter and year-to-year. We anticipate that our expenses will fluctuate substantially as we:

● continue our ongoing preclinical studies, clinical trials and our product development activities for our pipeline of product candidates;

● seek regulatory approvals for any product candidates that successfully complete clinical trials;

● continue research and preclinical development and initiate clinical trials of our other product candidates;

● seek to discover and develop additional product candidates either internally or in partnership with other pharmaceutical companies;

● adapt our regulatory compliance efforts to incorporate requirements applicable to marketed products;

● maintain, expand and protect our intellectual property portfolio; and

● incur additional legal, accounting and other expenses in operating as a public company.

Results of Operations

We are a development stage company currently performing clinical trials to obtain Food and Drug Administration (“FDA”) approval and commercialization of our product.

During the three months ended March 31, 2021, we incurred a loss from operations of $1,206,190 as compared to $520,736 for the three months ended March 31, 2020. The increase in the loss is due to an increase in research and development expense of $526,392 from $65,959 for the three months ended March 31, 2020 to $592,351 for the three months ended March 31 2021, and by an increase in general and administrative expenses of $159,062 from $454,777 for the three months ended March 31, 2020 to $613,839 for the three months ended March 31, 2021.

Liquidity and Going Concern

We continually project anticipated cash requirements, predominantly from the ongoing funding requirements of our neuropeptide drug development program. The majority of these expenses relate to paying external vendors such as Contract Research Organizations and peptide synthesizer companies. These expenses could also include business combinations, capital expenditures, and new drug development working capital requirements. As of March 31, 2021, we had cash of $191,674 and working capital of $454,826. We anticipate further losses from the development of our business. Based on its cash resources as of March 31, 2021, the Company has sufficient resources to fund its operations only through May 2021. However, based on cash resources that it received in April 2021 as a consequence of an equity offering, together with its current forecast and budget, management believes that the Company’s cash resources will be sufficient to fund its operations at least until the end of the third quarter of 2023. Absent generation of sufficient revenue from the execution of the Company’s business plan, the Company will need to obtain debt or equity financing by the third quarter of 2023. Because of these factors, the Company believes that this alleviates substantial doubt in connection with the Company’s ability to continue as a going concern.

Operating activities used $607,707 and $364,406 in cash for the three months ended March 31, 2021 and 2020, respectively. The use of cash in operating activities during the three months ended March 31, 2021, primarily comprised of $1,206,452 net loss, $345,975 in stock compensation expense, $83,670 of change in the fair value of the derivative liability since December 31, 2020, a decrease in prepaid expenses of $203,688, and a $78,777 increase of accounts payable and accrued expenses, which included payments to tax penalties, legal and accounting professionals, payments to consultants, and other administrative expenses.

Investing activities provided $0 and $0 in cash for the three months ended March 31, 2021 and 2020, respectively.

Financing activities provided $127,125 and $330,000 in cash the three months ended March 31, 2021 and 2020. The cash provided by operations came from proceeds from notes payable of $100,000 and exercise of warrants of $27,125.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Not applicable.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Evaluation of disclosure controls and procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Securities Exchange Act of 1934 (the “Exchange Act), as of March 31 2021. Based on this evaluation, we have identified a material weakness in our internal control over financial reporting. Due to this material weakness, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are not effective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act, including this Quarterly Report on Form 10-Q, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that our disclosure and controls are not designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Material Weakness in Internal Control Over Financial Reporting

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

The material weakness we identified is described below:

	1)	We do not have sufficient segregation of duties within accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Management evaluated the impact of our failure to have segregation of duties on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.
	2)	Limited level of multiple reviews among those tasked with preparing the financial statements.

This material weaknesses could result in a material misstatement to the annual or interim condensed consolidated financial statements that would not be prevented or detected.

Remediation Plan

To address the material weakness described above the Company has engaged an independent third party to enhance our segregation of duties.

Since we remain a small Company, with limited segregation of duties, the third party has identified certain areas where we can layer in added controls and procedures. Management intends to implement such controls and procedures in the future.

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the control system are met. The design of any system of controls is also based in part on certain assumptions regarding the likelihood of certain events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Given these and other inherent limitations of control systems, these are only reasonable assurances that our controls will succeed in achieving their stated goals under all potential future conditions.

Changes in Internal Control over Financial Reporting

Other than as discussed above, there were no changes in our internal controls over financial reporting that occurred during the quarter covered by this Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Part II: Other Information

Item 1. Legal Proceedings

Item 1A. Risk Factors

This Quarterly Report on Form 10-Q contains forward-looking information based on our current expectations. Because our actual results may differ materially from any forward-looking statements made by or on behalf of us, this section includes a discussion of important factors that could affect our actual future results, including our revenues, expenses, operating results, cash flows and net loss per share. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. You should carefully consider these risk factors, together with all of the other information included in this Quarterly Report on Form 10-Q as well as our other publicly available filings with the U.S. Securities and Exchange Commission, or SEC.

There have been no material changes to our risk factors from those disclosed under “Risk Factors” in Part I, Item 1A of the 2020 Form 10-K. The risks and uncertainties described below and in the 2020 Form 10-K are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also materially adversely affect our business, financial condition, or results of operations.

Item 2. Unregistered Sale of Equity Securities and Use of Proceeds

During the three months ended March 31, 2021, 10,000 options were exercised for 10,000 shares of the Company’s common stock.

During the three months ended March 31, 2021, 373,042 warrants were exercised for 240,123 shares of the Company’s common stock. The Company received $27,125 from these exercises.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

The following is a complete list of exhibits filed as part of this Form 10-Q. Exhibit numbers correspond to the numbers in the Exhibit Table of Item 601 of Regulation S-K.

Exhibit		Description

10.1		5.00% Promissory Note

31.1		Chief Executive Officer Certification as required under section 302 of the Sarbanes Oxley Act (€)

31.2		Chief Financial Officer Certification as required under section 302 of the Sarbanes Oxley Act (€)

32.1		Chief Executive Officer and Chief Financial Officer Certification pursuant to 18 U.S.C. section 1350 as adopted pursuant to section 906 of the Sarbanes Oxley Act *

101.INS		XBRL Instance Document (€)

101.CAL		XBRL Taxonomy Extension Schema Document (€)

101.SCH		XBRL Taxonomy Extension Calculation Linkbase Document (€)

101.LAB		XBRL Taxonomy Extension Label Linkbase Document (€)

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document (€)

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document (€)

(€)	- Filed herewith.

(*)	- Furnished, not filed, in accordance with item 601(32)(ii) of Regulation S-K.

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

May 17, 2021	Protagenic Therapeutics, Inc.

	By:	/s/ Alexander K. Arrow
		Chief Financial Officer

EX-10.1 2 ex10-1.htm

Exhibit 10.1

PROMISSORY NOTE

$100,000.00

March 1, 2021

For value received, PROTAGENIC THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), promises to pay to PATRICE MCNICOLL, an individual, or his assigns (the “Holder”), the principal sum of $100,000.00 (U.S. Dollars), together with all accrued and unpaid interest thereon as set forth below. Except as otherwise set forth herein, the principal and all accrued (and unpaid) interest of this promissory note (the “Note”) shall be due and payable by the Borrower on February 28, 2026 (the “Maturity Date”).

1. Payments. All payments will be made in lawful money of the United States of America at the principal office of the Borrower, or at such other place as the Holder may from time to time designate in writing to the Borrower. Payment will be credited first to accrued interest due and payable, with any remainder applied to principal. Prepayment of principal and interest, either in whole or in part, may be made by the Borrower, without penalty or premium, at any time prior to the Maturity Date; provided, however, that the Borrower shall give notice to the Holder of any such prepayment; and provided, further, that any partial prepayment of the Loan shall be in an amount not less than $25,000.

2. Security. This Note is a general unsecured obligation of the Company.

3. Interest Rate. Simple interest on the unpaid principal balance of this Note shall accrue at the lesser of five percent (5%) per annum and the highest rate permitted by law. If an Event of Default (as defined below) shall occur under this Note, interest shall immediately commence accruing at a default rate of twelve percent (7.5%) per annum.

4. Default. The occurrence of any of the following events of default (each, an “Event of Default”) shall, at the option of the Holder hereof, make all principal and interest (to the extent accrued) then remaining unpaid hereon and all other amounts payable hereunder immediately due and payable, upon written demand, without presentment, or grace period, all of which hereby are expressly waived, except as set forth below:

(a) Receiver or Trustee. The Borrower shall make an assignment for the benefit of creditors, or applies for or consents to the appointment of a receiver or trustee for it or for a substantial part of its property or business; or such a receiver or trustee shall otherwise be appointed without the consent of the Borrower, which shall constitute an automatic Event of Default and shall result in all remaining unpaid principal and interest due hereon immediately due and payable without the written demand from the Holder.

(b) Bankruptcy. Bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings or relief under any bankruptcy law or any law, or the issuance of any notice in relation to such event, for the relief of debtors shall be instituted by or against the Borrower, which shall constitute an automatic Event of Default and shall result in all remaining unpaid principal and interest due hereon immediately due and payable without the written demand from the Holder.

5. Termination. Upon payment of all cash amounts due to the Holder as provided in this Note, the Borrower will forever be released from all of its payment obligations and liabilities under this Note and the Holder agrees to promptly return to the Borrower the Note marked “paid in full.”

6. Other Agreements Upon the successful completion of a Qualified Financing, Borrower shall grant to Holder $25,000 in cash warrants, rounded to the nearest whole-number of warrants, to purchase the common stock of the Borrower. The warrants shall have (a) a 5-year term commencing with the date of the Qualified Financing and (b) a strike price equal to 110% of the offering price of the common stock in such Qualified Financing. For purposes of this Section 6, a “Qualified Financing” shall mean (i) a registered public offering of the common stock of the Borrower with gross proceeds of no less than $7.5 million and (ii) following the completion of such public offering, the common stock of the Borrower is listed on a national securities exchange. For example, if the qualified financing occurs at $5.00 per share, then Borrower shall grant 4,545 warrants, with a strike price of $5.50 per share, to Holder.

7. Miscellaneous.

(a) Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Note will inure to the benefit of, and be binding upon, the respective successors and assigns of the parties; provided, however, that the Borrower may not assign its obligations under this Note without the written consent of the Holder. This Note is for the sole benefit of the parties hereto and their respective successors and permitted assigns, and nothing herein, express or implied, is intended to or will confer upon any other person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Note.

(b) Severability. If one or more provisions of this Note are held to be unenforceable under applicable law, such provisions will be excluded from this Note and the balance of the Note will be interpreted as if such provisions were so excluded and this Note will be enforceable in accordance with its terms.

(c) Notice. Any notice or communication required to be given hereunder may be delivered by hand or deposited with an overnight courier (with overnight delivery instructions), if to the Borrower, to the address of the Borrower’s corporate headquarters, and if to the Holder, to the last address of the Holder set forth in the Borrower’s books and records. Notice shall be deemed given and received on the date sent if sent by personal delivery; and one (1) day after the date sent if sent by overnight courier.

(d) Counterparts. This Note may be executed in counterparts, each of which will be deemed an original, but all of which together will be deemed to be one and the same agreement. Counterparts may be delivered via facsimile, electronic mail (including PDF or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method, and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.

(e) Expenses. Each party will pay all costs and expenses that it incurs with respect to the negotiation, execution, delivery and performance of this Note.

(f) Entire Agreement; Amendments and Waivers. This Note constitutes the full and entire understanding and agreement between the parties with regard to the subject hereof. Any term of this Note may be amended and the observance of any term may be waived (either generally or in a particular instance and either retroactively or prospectively) with the written consent of the Borrower and the Holder. Any waiver or amendment effected in accordance with this Section 7(f) will be binding upon each future holder of this Note and the Borrower.

(g) Governing Law; Attorneys’ Fees. THIS NOTE WAS NEGOTIATED IN THE STATE OF NEW YORK, ANDMADE BY BORROWER AND ACCEPTED BY HOLDER IN THE STATE OF NEW YORK, AND THE PROCEEDS OF THIS NOTE WERE DISBURSED FROM THE STATE OF NEW YORK, WHICH STATE THE PARTIES AGREE HAS A SUBSTANTIAL RELATIONSHIP TO THE PARTIES AND TO THE UNDERLYING TRANSACTION EMBODIED HEREBY, AND IN ALL RESPECTS, INCLUDING, WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, MATTERS OF CONSTRUCTION, VALIDITY AND PERFORMANCE, THIS NOTE AND THE OBLIGATIONS ARISING HEREUNDER SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND PERFORMED IN SUCH STATE (WITHOUT REGARD TO PRINCIPLES OF CONFLICT LAWS) AND ANY APPLICABLE LAW OF THE UNITED STATES OF AMERICA. TO THE FULLEST EXTENT PERMITTED BY LAW, BORROWER HEREBY UNCONDITIONALLY AND IRREVOCABLY WAIVES ANY CLAIM TO ASSERT THAT THE LAW OF ANY OTHER JURISDICTION GOVERNS THIS NOTE AND THIS NOTE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK PURSUANT TO SECTION 5-1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW. ANY LEGAL SUIT, ACTION OR PROCEEDING AGAINST HOLDER OR BORROWER ARISING OUT OF OR RELATING TO THIS NOTE MAY AT HOLDER’S OPTION BE INSTITUTED IN ANY FEDERAL OR STATE COURT IN THE CITY OF NEW YORK, COUNTY OF NEW YORK, PURSUANT TO SECTION 5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW, AND BORROWER WAIVES ANY OBJECTIONS WHICH IT MAY NOW OR HEREAFTER HAVE BASED ON VENUE AND/OR FORUM NON CONVENIENS OF ANY SUCH SUIT, ACTION OR PROCEEDING, AND BORROWER HEREBY IRREVOCABLY SUBMITS TO THE JURISDICTION OF ANY SUCH COURT IN ANY SUIT, ACTION OR PROCEEDING.

(i) Subordination. By its acceptance hereof, the Holder agrees that the indebtedness evidenced by this Note, including the principal of and interest thereon, shall be subordinate to and subject in right of payment, to the extent hereinafter set forth, to the prior payment in full of all principal, interest and any other sums then due on all existing or future Senior Indebtedness of the Borrower. The term “Senior Indebtedness” shall mean secured and unsecured indebtedness of the Borrower, or with respect to which the Borrower is a guarantor, for money borrowed by the Borrower from any financial institution.

IN WITNESS WHEREOF, the Borrower has executed this Note as of the date set forth above.

	PROTAGENIC THERAPEUTICS, INC.,
	a Delaware corporation

	By:
		Garo Armen, Executive Chairman

EX-31.1 3 ex31-1.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13a-14(a) OF THE

SECURITIES EXCHANGE ACT OF 1934

I, Garo H. Armen, PhD, certify that:

	1.	I have reviewed this quarterly report on Form 10-Q of Protagenic Therapeutics, Inc..

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

May 17, 2021		/s/ Garo H. Armen
	Name:	Garo H. Armen, Ph.D.
	Title:	Executive Chairman

EX-31.2 4 ex31-2.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO RULE 13a-14(a) OF THE

SECURITIES EXCHANGE ACT OF 1934

I, Garo H. Armen, PhD, certify that:

	1.	I have reviewed this quarterly report on Form 10-Q of Protagenic Therapeutics, Inc..

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

May 17, 2021		/s/ Garo H. Armen
	Name:	Garo H. Armen, Ph.D.
	Title:	Executive Chairman

EX-32.1 5 ex32-1.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES OXLEY ACT OF 2002

In connection with the Quarterly Report of Protagenic Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Garo H. Armen, Executive Chairman, and Alexander K. Arrow, Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

May 17, 2021	By:	/s/ Garo H. Armen
		Garo H. Armen, PhD
		Executive Chairman
		(Principal Executive Officer)

May 17, 2021	By:	/s/ Alexander K. Arrow
		Alexander K. Arrow, MD, CFA
		Chief Financial Officer
		(Principal Financial Officer)

EX-101.INS 6 ptix-20210331.xml XBRL INSTANCE FILE 0001022899 PTIX:UniversityOfTorontoMember 2015-01-01 2015-12-31 0001022899 PTIX:UniversityOfTorontoMember 2015-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2020-12-31 0001022899 2021-01-01 2021-03-31 0001022899 2019-12-31 0001022899 srt:MinimumMember 2020-01-01 2020-12-31 0001022899 srt:MaximumMember 2020-01-01 2020-12-31 0001022899 PTIX:ConsultantMember 2019-10-02 0001022899 PTIX:UnsecuredConvertibleNotesMember 2020-12-31 0001022899 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-12-31 0001022899 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001022899 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001022899 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001022899 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-12-31 0001022899 us-gaap:MeasurementInputExercisePriceMember 2020-12-31 0001022899 us-gaap:MeasurementInputExpectedTermMember 2020-01-01 2020-12-31 0001022899 PTIX:ToxicologyStudiesMember 2020-12-31 0001022899 PTIX:UnsecuredConvertibleNotesWithRelatedPartiesMember 2020-12-31 0001022899 us-gaap:EmployeeStockOptionMember PTIX:FiveIndividualsMember 2021-02-24 2021-02-25 0001022899 us-gaap:EmployeeStockOptionMember PTIX:RelatedPartiesMember 2020-02-24 2020-02-25 0001022899 us-gaap:EmployeeStockOptionMember PTIX:SettlementOfAccruedCompensationMember 2020-02-24 2020-02-25 0001022899 us-gaap:EmployeeStockOptionMember PTIX:OptionsVestedOverFourtyEightMonthsMember 2021-02-24 2021-02-25 0001022899 us-gaap:EmployeeStockOptionMember PTIX:OptionsVestedOverFourtyEightMonthsMember 2020-02-24 2020-02-25 0001022899 us-gaap:WarrantMember 2020-12-31 0001022899 us-gaap:WarrantMember 2021-03-31 0001022899 srt:MinimumMember 2021-01-01 2021-03-31 0001022899 srt:MaximumMember 2021-01-01 2021-03-31 0001022899 PTIX:DrDavidLovejoyMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001022899 PTIX:DrDavidLovejoyMember us-gaap:EmployeeStockOptionMember 2021-03-31 0001022899 PTIX:DrDavidLovejoyMember us-gaap:EmployeeStockOptionMember srt:MinimumMember 2021-03-31 0001022899 PTIX:DrDavidLovejoyMember us-gaap:EmployeeStockOptionMember srt:MaximumMember 2021-03-31 0001022899 us-gaap:LicensingAgreementsMember 2021-03-31 0001022899 PTIX:RelatedPartyMember 2020-02-24 2020-02-25 0001022899 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001022899 us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0001022899 us-gaap:MeasurementInputPriceVolatilityMember 2020-12-31 0001022899 PTIX:OptionsToRelatedPartyMember 2021-03-31 0001022899 PTIX:OptionsToRelatedPartyMember 2021-01-01 2021-03-31 0001022899 2020-12-31 0001022899 PTIX:DrDavidLovejoyMember us-gaap:EmployeeStockOptionMember srt:MinimumMember 2021-01-01 2021-03-31 0001022899 PTIX:DrDavidLovejoyMember us-gaap:EmployeeStockOptionMember srt:MaximumMember 2021-01-01 2021-03-31 0001022899 PTIX:TwoThousandSixteenPlanMember 2017-01-01 2017-01-02 0001022899 PTIX:TwoThousandSixteenPlanMember 2017-01-02 0001022899 PTIX:TwoThousandSixteenPlanMember 2019-01-01 2019-01-02 0001022899 PTIX:TwoThousandSixteenPlanMember 2019-01-02 0001022899 PTIX:TwoThousandSixteenPlanMember 2020-01-01 2020-01-02 0001022899 PTIX:TwoThousandSixteenPlanMember 2020-01-02 0001022899 PTIX:TwoThousandSixteenPlanMember 2020-12-31 0001022899 srt:ScenarioForecastMember 2021-04-28 2021-04-29 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2019-12-31 0001022899 us-gaap:CommonStockMember 2019-12-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001022899 us-gaap:RetainedEarningsMember 2019-12-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2020-12-31 0001022899 us-gaap:CommonStockMember 2020-12-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001022899 us-gaap:RetainedEarningsMember 2020-12-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001022899 2021-03-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2021-03-31 0001022899 2020-01-01 2020-03-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2020-03-31 0001022899 PTIX:SeriesBConvertiblePreferredStockMember 2021-03-31 0001022899 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001022899 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001022899 us-gaap:CommonStockMember 2020-03-31 0001022899 us-gaap:CommonStockMember 2021-03-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001022899 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001022899 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001022899 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001022899 us-gaap:RetainedEarningsMember 2020-03-31 0001022899 us-gaap:RetainedEarningsMember 2021-03-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001022899 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001022899 2020-03-31 0001022899 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-03-31 0001022899 PTIX:ConvertibleNotesPayableRelatedPartyMember 2021-01-01 2021-03-31 0001022899 us-gaap:EquipmentMember 2021-01-01 2021-03-31 0001022899 2020-01-01 2020-12-31 0001022899 us-gaap:PrivatePlacementMember 2021-01-01 2021-03-31 0001022899 us-gaap:PrivatePlacementMember 2021-03-31 0001022899 us-gaap:MeasurementInputExpectedDividendRateMember 2021-03-31 0001022899 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-03-31 0001022899 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-03-31 0001022899 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-03-31 0001022899 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-03-31 0001022899 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-03-31 0001022899 PTIX:ConversionFeatureSharesMember 2021-01-01 2021-03-31 0001022899 us-gaap:StockOptionMember 2021-01-01 2021-03-31 0001022899 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001022899 PTIX:ConvertibleNotesMember 2021-01-01 2021-03-31 0001022899 PTIX:ToxicologyStudiesMember 2021-01-01 2021-03-31 0001022899 PTIX:ToxicologyStudiesMember 2021-03-31 0001022899 PTIX:ToxicologyStudiesMember 2020-12-30 2020-12-31 0001022899 PTIX:PromissoryNoteMember 2021-03-01 0001022899 PTIX:PromissoryNoteMember 2021-01-01 2021-03-31 0001022899 PTIX:PromissoryNoteMember srt:MaximumMember 2021-03-01 0001022899 PTIX:UnsecuredConvertibleNotesMember 2021-03-31 0001022899 PTIX:UnsecuredConvertibleNotesMember 2021-01-01 2021-03-31 0001022899 PTIX:UnsecuredConvertibleNotesWithRelatedPartiesMember 2021-01-01 2021-03-31 0001022899 PTIX:UnsecuredConvertibleNotesWithRelatedPartiesMember 2020-01-01 2020-03-31 0001022899 PTIX:UnsecuredConvertibleNotesWithRelatedPartiesMember 2021-03-31 0001022899 PTIX:PromissoryNoteMember 2021-03-31 0001022899 PTIX:PromissoryNoteMember 2020-12-31 0001022899 us-gaap:ConvertibleNotesPayableMember 2021-03-31 0001022899 PTIX:ConvertibleNotesPayableRelatedPartyMember 2021-03-31 0001022899 PTIX:TwoThousandSixteenPlanMember 2021-03-31 0001022899 PTIX:TwoThousandSixteenPlanMember 2021-01-01 2021-03-31 0001022899 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001022899 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001022899 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001022899 PTIX:EmployeesMember 2021-01-01 2021-03-31 0001022899 PTIX:NonEmployeesMember 2021-01-01 2021-03-31 0001022899 us-gaap:StockOptionMember 2021-03-31 0001022899 PTIX:NonEmployeesMember 2021-03-31 0001022899 PTIX:EmployeesMember 2021-03-31 0001022899 PTIX:ResearchAgreementsMember 2021-01-01 2021-03-31 0001022899 PTIX:ResearchAgreementsMember 2020-01-01 2020-03-31 0001022899 PTIX:FiveIndividualsMember 2020-02-24 2020-02-25 0001022899 2020-02-25 0001022899 srt:MinimumMember 2020-02-24 2020-02-25 0001022899 srt:MaximumMember 2020-02-24 2020-02-25 0001022899 us-gaap:SubsequentEventMember 2021-04-01 2021-05-15 0001022899 us-gaap:SubsequentEventMember 2021-05-15 0001022899 us-gaap:SubsequentEventMember PTIX:RelatedPartyMember 2021-04-01 2021-05-15 0001022899 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2021-04-01 2021-05-15 0001022899 srt:ScenarioForecastMember us-gaap:IPOMember 2021-04-28 2021-04-29 0001022899 srt:ScenarioForecastMember us-gaap:IPOMember 2021-04-29 0001022899 srt:ScenarioForecastMember us-gaap:IPOMember PTIX:FourtyFiveDayOptionMember 2021-04-28 2021-04-29 0001022899 srt:ScenarioForecastMember us-gaap:IPOMember PTIX:FourtyFiveDayOptionMember 2021-04-29 0001022899 2021-05-14 0001022899 PTIX:ConversionFeatureSharesMember 2020-01-01 2020-03-31 0001022899 us-gaap:StockOptionMember 2020-01-01 2020-03-31 0001022899 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001022899 PTIX:ConvertibleNotesMember 2020-01-01 2020-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure Protagenic Therapeutics, Inc.\new 10-Q 2021-03-31 false --12-31 Non-accelerated Filer Q1

592351

65959

2021

-1206452

-498589

-1206452

true false

0.000001

18000000

20000000

18000000

872766

0.0001

100000000

10360480

10610603

10360480

10610603

Yes Yes false 0001022899

1.00

1.76

5.60

P6Y5M23D

P5Y

P10Y

879247

196142

-171586

-171095

-17698936

-18905388

16719749

17092824

1036

1061

2028983

2178739

292412 301723

1081384

1126048

655187

650968

83670

571517

650968

879247

196142

879247

196142

208156

4468

671091

191674

10520484

10261419

-0.11

-0.05

-1205961

-501008

491

-2419

-1206452

-498589

-262

22147

83937

38986

384

-1206190

-520736

1206190

520736

613839

454777

753972

671091

191674

753972

-479417

-44651

-634366

-1149736

1026

14687172

-15150201

-172364

1036

16719749

-17698936

-171586

-1982597

1026

1061

15236623

17092824

-15648790

-18905388

-174783

-171095

-585923

83670

60749

345975

360436

53975

27357

44664

9311

9414

-5861

-203688

-11669

78777

-210475

-607707

-364406

27125

100000

330000

127125

330000

1165

-10245

89204

295945

-83670

83670

1.25

0.09

0.00

169

0.00

P1M20D

11628394

9425106

872766

5673861

3483767

1598000

872766

3925682

3826658

800000

988000

174106

319799

36161 36161 393496 381062

141860

233745

0.05

1.10

2026-02-28

127346

25000

516116

107588

471452

98277

1597500

400000

100000

1697500

400000

93950

564378

1693134

4868623

P10Y

P13Y

P10Y

10000

5597861

5673861

38328

23025089

366000

350000

2009063

350000

366000

1387497

366000

360000

5.60

345975

360436

325794

344499

1476

34641

136203

209772

2778726 2380966 397760

106291

16000

350000

431112

4.70

695137

3180000

477000

3483767

4007058

3483767

782668 16684157

25000

553299

1.00

1.25

1.75

Exercisable over a ten year period which ends on April 1, 2022. These have an exercise price of $1.00, $1.25 or 1.75 and are exercisable over ten or thirteen year periods which end either on March 30, 2021, December 1, 2022, April 15, 2026, March 1, 2027, October 16, 2027 or on February 13, 2030. 0.025 0.10 0.025

0.03

1.00

493177

231277

360000

3180000

477000

872766

10261419

872766

10360480

872766

10261419

10610603

491

-2419

491

345975

360436

345975

89204

93950 93950 14643780 5861 5861

-1

10000

P3Y

2021-02-21

400000

100000

7500000

400000

100000

0.075

280000

1.00

P9Y8M9D P6Y9M11D

862833

1122542

1.75

2.93

5.60

1.06 1.03 P1Y10M10D P1Y10M6D

1.75

5.60

0.00

0.0064

0.0161

0.0081

0.0154

P5Y

P10Y

1.40

1.46

1.49

1.58

1.03

373042

240123

27125 1.25 1.25 100000

532500

11400000

150249

373042

27125 24 27101 240123 100000

NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS   Company Background   Protagenic Therapeutics, Inc. (“we,” “our,” “Protagenic” or “the Company”), is a Delaware corporation with one subsidiary named Protagenic Therapeutics Canada (2006) Inc. (“PTI Canada”), a corporation formed in 2006 under the laws of the Province of Ontario, Canada.   The Company was previously known as Atrinsic, Inc., a company that was once a reporting company under the Securities Exchange Act of 1934, but that, in 2012 and 2013, reorganized under Chapter 11 of the United States Bankruptcy Code and emerged from bankruptcy. On February 12, 2016, the Company acquired Protagenic Therapeutics, Inc. (“Prior Protagenic”) through a reverse merger.   On February 12, 2016, Protagenic Acquisition Corp., a wholly-owned subsidiary of the Company, merged (the “Merger”) with and into Prior Protagenic. Prior Protagenic was the surviving corporation of the Merger. As a result of the Merger, the Company acquired the business of Prior Protagenic and has continued the existing business operations of Prior Protagenic as a wholly-owned subsidiary. On June 17, 2016, Prior Protagenic merged with and into the Company with the Company as the surviving corporation in the merger. Immediately thereafter, the Company changed its name from Atrinsic, Inc. to Protagenic Therapeutics, Inc.

NOTE 2 - LIQUIDITY   As shown in the accompanying consolidated financial statements, the Company has incurred significant recurring losses resulting in an accumulated deficit. The Company anticipates further losses in the development of its business. The Company had negative cash flows used in operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.   Based on its cash resources as of March 31, 2021, the Company has sufficient resources to fund its operations only through May 2021. However, based on cash resources that it received in April 2021 as a consequence of an equity offering, together with its current forecast and budget, management believes that its cash resources will be sufficient to fund its operations at least until the end of the third quarter of 2023. Absent generation of sufficient revenue from the execution of the Company’s business plan and sales revenue is not anticipated before 2024, the Company will need to obtain debt or equity financing by the third quarter of 2023. Because of these factors, the Company believes that this alleviates the substantial doubt in connection with the Company’s ability to continue as a going concern.

NOTE 3 - SUMMARY OF SIGNFICANT ACCOUNTING POLICIES   Basis of presentation   The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC” for interim financial information. In the opinion of the Company’s management, the accompanying consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended March 31, 2021 and 2020. Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”).   The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s financial statements for the year ended December 31, 2020, which contain the audited financial statements and notes thereto, for the years ended December 31, 2020 and 2019 included within the Company’s Form 10-K filed with the SEC on March 25, 2021. The interim results for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.   Principles of consolidation   The condensed consolidated financial statements include the accounts of Protagenic Therapeutics, Inc., and its wholly owned Canadian subsidiary, PTI Canada. All significant intercompany balances and transactions have been eliminated in the condensed consolidated financial statements.   Reclassifications:   Reclassifications of prior periods have been made to conform with current year presentation   Use of estimates   The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the condensed consolidated financial statements include income tax provisions, valuation of stock options and warrants and assessment of deferred tax asset valuation allowance.   Concentrations of Credit Risk   The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.   Cash and Cash Equivalents   The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of March 31, 2021 and December 31, 2020, the Company did not have any cash equivalents.   Fair Value Measurements   ASC 820, “Fair Value Measurements and Disclosure,” defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).   The three levels are described below:   Level 1 Inputs – Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company;   Level 2 Inputs – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;   Level 3 Inputs – Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.   The carrying amount of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair value because of the short term maturity of those instruments. The carrying value of long-term debt approximates fair value since the related rates of interest approximate current market rates.   Transactions involving related parties cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm’s-length transactions unless such representations can be substantiated.   The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of March 31, 2021.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Carrying</td> <td> </td> <td> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value Measurement Using</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Value</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 40%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Derivative warrants liabilities</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td></tr> </table>   The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2020.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Carrying</td> <td> </td> <td> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value Measurement Using</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Value</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 40%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Derivative warrants liabilities</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">83,670</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">83,670</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">83,670</td> <td> </td></tr> </table>   The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2021 and the year ended December 31, 2020:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2"> Fair Value Measurement Using Level 3</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Inputs Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%">Balance, December 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">83,670</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Change in fair value of derivative warrants liabilities</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(83,670</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Balance, March 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   The fair value of the derivative feature of the 127,346 and 295,945 warrants issued to the placement agent of the Company’s 2016 private offering (the “2016 Offering”) and to a holder of its debt for debt cancellation in connection with the Merger, respectively on the issuance dates and at the balance sheet dates were calculated using a Black-Scholes option model valued with the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%">Exercise price</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">1.25</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Risk free interest rate</td> <td> </td> <td> </td> <td style="text-align: right">0.09</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">169</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Contractual term</td> <td> </td> <td> </td> <td style="text-align: right">0.14 Years</td> <td> </td></tr> </table>   Risk-free interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note with a similar expected term on the date of measurement.   Dividend yield: The Company uses a 0% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring dividends in the near future.   Volatility: The Company calculates the expected volatility of the stock price based on the corresponding volatility of the Company’s peer group stock price for a period consistent with the warrants’ expected term.   Expected term: The Company’s expected term is based on the remaining contractual maturity of the warrants.   During the three months ended March 31, 2021 and 2020, the Company marked the derivative feature of the warrants to fair value and recorded a gain of $83,670 and a gain of $60,749 relating to the change in fair value, respectively. The warrants expired on February 21, 2021, resulting in the elimination of the derivative liability.   Derivative Liability   The Company evaluates its options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815-10-05-4 and 815-40-25. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as either an asset or a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the condensed consolidated statements of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation and then the related fair value is reclassified to equity.   The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.   Stock-Based Compensation   The Company accounts for stock based compensation costs under the provisions of ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense related to the fair value of stock based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock based payments granted to employees, officers, non-employees, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC. 718 is also applied to awards modified, repurchased, or canceled during the periods reported.   If any award granted under the Company’s 2016 Equity Compensation Plan (the “2016 Plan”) payable in shares of common stock is forfeited, cancelled, or returned for failure to satisfy vesting requirements, otherwise terminates without payment being made, or if shares of common stock are withheld to cover withholding taxes on options or other awards, the number of shares of common stock as to which such option or award was forfeited, or which were withheld, will be available for future grants under the 2016 Plan. The Company recognizes the impact of forfeitures when they occur.   Basic and Diluted Net (Loss) per Common Share   Basic (loss) per common share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the condensed consolidated statements of operations.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Potentially Outstanding Dilutive Common Shares</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended March 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended March 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Conversion Feature Shares</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Common shares issuable under the conversion feature of preferred shares</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">872,766</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">872,766</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Stock Options</td> <td> </td> <td> </td> <td style="text-align: right">5,673,861</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,925,682</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Warrants</td> <td> </td> <td> </td> <td style="text-align: right">3,483,767</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,826,658</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Convertible Notes</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,598,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">800,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total potentially outstanding dilutive common shares</td> <td> </td> <td> </td> <td style="text-align: right">11,628,394</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,425,106</td> <td> </td></tr> </table>   Research and Development   Research and development expenses are charged to operations as incurred.   Foreign Currency Translation   The Company follows Section 830-10-45 of the FASB Accounting Standards Codification (“Section 830-10-45”) for foreign currency translation to translate the financial statements of the foreign subsidiary from the functional currency, generally the local currency, into U.S. Dollars. Section 830-10-45 sets out the guidance relating to how a reporting entity determines the functional currency of a foreign entity (including of a foreign entity in a highly inflationary economy), re-measures the books of record (if necessary), and characterizes transaction gains and losses. Pursuant to Section 830-10-45, the assets, liabilities, and operations of a foreign entity shall be measured using the functional currency of that entity. An entity’s functional currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the environment, or local currency, in which an entity primarily generates and expends cash.   The functional currency of each foreign subsidiary is determined based on management’s judgment and involves consideration of all relevant economic facts and circumstances affecting the subsidiary. Generally, the currency in which the subsidiary transacts a majority of its transactions, including billings, financing, payroll and other expenditures, would be considered the functional currency, but any dependency upon the parent and the nature of the subsidiary’s operations must also be considered. If a subsidiary’s functional currency is deemed to be the local currency, then any gain or loss associated with the translation of that subsidiary’s financial statements is included in accumulated other comprehensive income. However, if the functional currency is deemed to be the U.S. Dollar, then any gain or loss associated with the re-measurement of these financial statements from the local currency to the functional currency would be included in the condensed consolidated statements of operations and comprehensive income (loss). If the Company disposes of foreign subsidiaries, then any cumulative translation gains or losses would be recorded into the condensed consolidated statements of operations and comprehensive income (loss). If the Company determines that there has been a change in the functional currency of a subsidiary to the U.S. Dollar, any translation gains or losses arising after the date of change would be included within the condensed consolidated statements of operations and comprehensive income (loss).   Based on an assessment of the factors discussed above, the management of the Company determined its subsidiary’s local currency (i.e. the Canadian dollar) to be the functional currency for its foreign subsidiary.   Recent Accounting Pronouncements   Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

NOTE 4 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES   Accounts payable and accrued expenses consist of the following at:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">March 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Accounting</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">36,161</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">36,161</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Research and development</td> <td> </td> <td> </td> <td style="text-align: right">381,062</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">393,496</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Other</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">233,745</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">141,860</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">650,968</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">571,517</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   On October 1, 2019, the Company entered into an agreement with a consultant for toxicology studies. The consultant quoted a commitment of approximately $988,000 as an estimate for the study. 50% of the total price was paid upon the signing of the agreement, 35% of the total price is to be paid upon completion of the in-life study, and the remaining 15% of the total price is to be paid upon the issuance of the report. If the Company cancels the study the Company will be required to pay a cancelation fee. If the cancelation happens prior to the arrival of the test animals then the Company will need to pay between 20% and 50% of the animal fees depending on when the cancellation happens. If the cancellation occurs after the animals arrive but before the study begins then the Company will be responsible for paying 50% of the protocol price plus a fee of $7,000 per room/week for animal husbandry until the animals can be relocated or disposed of. If the Company cancels the study after it has begun then the Company will need to pay any fees for procured items for the study and any nonrecoverable expenses incurred by the consultant. As of March 31, 2021 and December 31, 2020, the Company has paid $174,106 and $174,106 to the consultant and there is a balance of $319,799 and $319,799 due, respectively.

NOTE 5 – NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES)   Note Payable   On March 1, 2021, the Company entered into a $100,000 promissory note. This note is due on February 28, 2026 and accrues interest at a rate of 5% per annum or 7.5% per annum in the case of default. In the event that the Company completes a financing of no less than $7.5 million, then the note holder will be issued warrants valued at $25,000 with an exercise price equal to 110% of the offering cost of the common stock in the financing. These warrants will have a term of five years.   As of March 31, 2021 and December 31, 2020, the Company owes $100,000 and $0 on the outstanding Note, respectively.   Convertible Notes Payable   During the three months ended March 31, 2021 and 2020, the Company amortized $44,664 and $17,943 of the debt discount, respectively. At March 31, 2021 and December 31, 2020, the Company had an unamortized debt discount of $471,452 and $516,116, respectively.   As of March 31, 2021 and December 31, 2020, the Company owes $1,597,500 and $1,597,500 on the outstanding Convertible Notes, respectively.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">Maturity Date of Notes for Twelve Months Ending March 31, 2021,</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Amount due</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">2022</td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2023</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; text-align: justify">2024</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">1,597,500</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2025</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; text-align: justify">2026</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">100,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: justify">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,697,500</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Convertible Notes Payable – Related Parties   During the three months ended March 31, 2021 and 2020, the Company amortized $9,311 and $9,414 of the debt discount, respectively. At March 31, 2021 and December 31, 2020, the Company had an unamortized debt discount of $98,277 and $107,588, respectively.   As of March 31, 2021 and December 31, 2020, the Company owes $400,000 and $400,000 on the outstanding Convertible Notes, respectively.     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">Maturity Date of Notes for Twelve Months Ending March 31, 2021,</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Amount due</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">2022</td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2023</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; text-align: justify">2024</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">400,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2025</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; text-align: justify">2026</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: justify">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">400,000</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

NOTE 7 - COLLABORATIVE AGREEMENTS   The Company and the University of Toronto (the “University”) entered into an agreement effective April 1, 2014 (the “New Research Agreement”) for the performance of a research project titled “Teneurin C-terminal Associated Peptide (“TCAP”) mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism” (the “New Project”). The New Project is to perform research related to work done by Dr. David A. Lovejoy, a professor at the University and stockholder of the Company, in regard to TCAP mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism. In addition to the New Research Agreement, Dr. Lovejoy entered into an agreement with the University in order to commercialize certain technologies. The New Research Agreement expired on March 30, 2016. In February 2017, the New Research Agreement was extended to December 31, 2017. The extension allowed for further development of the technologies and use of their applications. On April 10, 2018, the agreement was amended and the research agreement has been further extended to December 31, 2023.   Prior to January 1, 2016, the University has been granted 25,000 stock options which are fully vested at the exercise price of $1.00 exercisable over a ten year period which ends on April 1, 2022. As of March 31, 2021, Dr. David Lovejoy of the University has been granted 553,299 stock options, of which 431,112 are fully vested and 100,000 have expired. These have an exercise price of $1.00, $1.25 or 1.75 and are exercisable over ten or thirteen year periods which end either on March 30, 2021, December 1, 2022, April 15, 2026, March 1, 2027, October 16, 2027 or on February 13, 2030.   The sponsorship research and development expenses pertaining to the Research Agreements were $0 and $0 for the three months ended March 31, 2021 and 2020, respectively.

NOTE 8 - COMMITMENTS AND CONTINGENCIES   Licensing Agreements   On July 31, 2005, the Company had entered into a Technology License Agreement (“License Agreement”) with the University pursuant to which the University agreed to license to the Company patent rights and other intellectual property, among other things (the “Technologies”). The Technology License Agreement was amended on February 18, 2015 and currently does not provide for an expiration date.   Pursuant to the License Agreement and its amendment, the Company obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement and amendment. In consideration, the Company agreed to pay to the University a royalty payment of 2.5% of net sales of any product based on the Technologies. If the Company elects to sublicense any rights under the License Agreement and amendment, the Company agrees to pay to the University 10% of any up-front sub-license fees for any sub-licenses that occurred on or after September 9, 2006, and, on behalf of the sub-licensee, 2.5% of net sales by the sub-licensee of all products based on the Technologies. The Company had no sales revenue for the three months ended March 31, 2021 and 2020 and therefore was not subject to paying any royalties.   In the event the Company fails to provide the University with semi-annual reports on the progress or fails to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, the University may convert our exclusive license into a non-exclusive arrangement. Interest on any amounts owed under the License Agreement and amendment will be at 3% per annum. All intellectual property rights resulting from the Technologies or improvements thereon will remain the property of the other inventors and/or Dr. Lovejoy, and/or the University, as the case may be. The Company has agreed to pay all out-of- pocket filing, prosecution and maintenance expenses in connection with any patents relating to the Technologies. In the case of infringement upon any patents relating to the Technologies, the Company may elect, at its own expense, to bring a cause of action asserting such infringement. In such a case, after deducting any legal expenses the Company may incur, any settlement proceeds will be subject to the 2.5% royalty payment owed to the University under the License Agreement and amendment.   The patent applications were made in the name of Dr. Lovejoy and other inventors, but the Company’s exclusive, worldwide rights to such patent applications are included in the License Agreement and its amendment with the University. The Company maintains exclusive licensing agreements and it currently controls the five intellectual patent properties.   Legal Proceedings   From time to time we may be named in claims arising in the ordinary course of business. Currently, no legal proceedings, government actions, administrative actions, investigations or claims are pending against us or involve us that, in the opinion of our management, could reasonably be expected to have a material adverse effect on our business and financial condition.

NOTE 9 – RELATED PARTY TRANSACTIONS   The Company is provided free office space consisting of a conference room by the Company Executive Chairman, Dr. Armen. The Company does not pay any rent for the use of this space. This space is used for quarterly board meetings and our annual shareholder meeting.   On February 25, 2021, the Company issued 366,000 options to purchase common stock to 5 individuals, with 350,000 of those options going to related parties. These options had an exercise price of $5.60 and a term of 5 or 10 years. (See Note 6)

NOTE 10- SUBSEQUENT EVENTS   Subsequent to the period, the Company issued 493,177 shares of the Company’s common stock for the net exercise of 695,137 warrants. 231,277 of these shares of common stock were issued to a related party.   Subsequent to the period, the Company issued 360,000 shares of the Company’s common stock for the exercise of 360,000 options. The Company received proceeds of $532,500 from the exercise.   On April, 29, 2021, the Company completed a public offering (“the Offering”) to sell aggregate of 3,180,000 shares of the Company’s common stock together with warrants to purchase an aggregate of 3,180,000 shares of common stock. The Company also granted the underwriters a 45-day option to purchase up to an additional 477,000 shares of Common Stock (the “Option Shares”) and/or warrants to purchase an aggregate of 477,000 shares of Common Stock at the same price. Net proceeds from the Offering were approximately $11.4 million (excluding any sale of the Option Shares), after deducting underwriting discounts and commissions and public offering expenses payable by the Company.

Basis of presentation   The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC” for interim financial information. In the opinion of the Company’s management, the accompanying consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended March 31, 2021 and 2020. Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”).   The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s financial statements for the year ended December 31, 2020, which contain the audited financial statements and notes thereto, for the years ended December 31, 2020 and 2019 included within the Company’s Form 10-K filed with the SEC on March 25, 2021. The interim results for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.

Principles of consolidation   The condensed consolidated financial statements include the accounts of Protagenic Therapeutics, Inc., and its wholly owned Canadian subsidiary, PTI Canada. All significant intercompany balances and transactions have been eliminated in the condensed consolidated financial statements.

Reclassifications:   Reclassifications of prior periods have been made to conform with current year presentation

Use of estimates   The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the condensed consolidated financial statements include income tax provisions, valuation of stock options and warrants and assessment of deferred tax asset valuation allowance.

Concentrations of Credit Risk   The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.

Cash and Cash Equivalents   The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of March 31, 2021 and December 31, 2020, the Company did not have any cash equivalents.

Fair Value Measurements   ASC 820, “Fair Value Measurements and Disclosure,” defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).   The three levels are described below:   Level 1 Inputs – Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company;   Level 2 Inputs – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;   Level 3 Inputs – Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.   The carrying amount of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair value because of the short term maturity of those instruments. The carrying value of long-term debt approximates fair value since the related rates of interest approximate current market rates.   Transactions involving related parties cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm’s-length transactions unless such representations can be substantiated.   The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of March 31, 2021.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Carrying</td> <td> </td> <td> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value Measurement Using</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Value</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 40%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Derivative warrants liabilities</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td></tr> </table>   The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2020.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Carrying</td> <td> </td> <td> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value Measurement Using</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Value</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 40%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Derivative warrants liabilities</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">83,670</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">83,670</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">83,670</td> <td> </td></tr> </table>   The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2021 and the year ended December 31, 2020:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2"> Fair Value Measurement Using Level 3</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Inputs Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%">Balance, December 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">83,670</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Change in fair value of derivative warrants liabilities</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(83,670</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Balance, March 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   The fair value of the derivative feature of the 127,346 and 295,945 warrants issued to the placement agent of the Company’s 2016 private offering (the “2016 Offering”) and to a holder of its debt for debt cancellation in connection with the Merger, respectively on the issuance dates and at the balance sheet dates were calculated using a Black-Scholes option model valued with the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%">Exercise price</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">1.25</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Risk free interest rate</td> <td> </td> <td> </td> <td style="text-align: right">0.09</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">169</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Contractual term</td> <td> </td> <td> </td> <td style="text-align: right">0.14 Years</td> <td> </td></tr> </table>   Risk-free interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note with a similar expected term on the date of measurement.   Dividend yield: The Company uses a 0% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring dividends in the near future.   Volatility: The Company calculates the expected volatility of the stock price based on the corresponding volatility of the Company’s peer group stock price for a period consistent with the warrants’ expected term.   Expected term: The Company’s expected term is based on the remaining contractual maturity of the warrants.   During the three months ended March 31, 2021 and 2020, the Company marked the derivative feature of the warrants to fair value and recorded a gain of $83,670 and a gain of $60,749 relating to the change in fair value, respectively. The warrants expired on February 21, 2021, resulting in the elimination of the derivative liability.

Derivative Liability   The Company evaluates its options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815-10-05-4 and 815-40-25. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as either an asset or a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the condensed consolidated statements of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation and then the related fair value is reclassified to equity.   The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.

Stock-Based Compensation   The Company accounts for stock based compensation costs under the provisions of ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense related to the fair value of stock based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock based payments granted to employees, officers, non-employees, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC. 718 is also applied to awards modified, repurchased, or canceled during the periods reported.   If any award granted under the Company’s 2016 Equity Compensation Plan (the “2016 Plan”) payable in shares of common stock is forfeited, cancelled, or returned for failure to satisfy vesting requirements, otherwise terminates without payment being made, or if shares of common stock are withheld to cover withholding taxes on options or other awards, the number of shares of common stock as to which such option or award was forfeited, or which were withheld, will be available for future grants under the 2016 Plan. The Company recognizes the impact of forfeitures when they occur.

Basic and Diluted Net (Loss) per Common Share   Basic (loss) per common share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the condensed consolidated statements of operations.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Potentially Outstanding Dilutive Common Shares</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended March 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended March 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Conversion Feature Shares</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Common shares issuable under the conversion feature of preferred shares</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">872,766</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">872,766</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Stock Options</td> <td> </td> <td> </td> <td style="text-align: right">5,673,861</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,925,682</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Warrants</td> <td> </td> <td> </td> <td style="text-align: right">3,483,767</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,826,658</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Convertible Notes</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,598,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">800,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total potentially outstanding dilutive common shares</td> <td> </td> <td> </td> <td style="text-align: right">11,628,394</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,425,106</td> <td> </td></tr> </table>

Research and Development   Research and development expenses are charged to operations as incurred.

Foreign Currency Translation   The Company follows Section 830-10-45 of the FASB Accounting Standards Codification (“Section 830-10-45”) for foreign currency translation to translate the financial statements of the foreign subsidiary from the functional currency, generally the local currency, into U.S. Dollars. Section 830-10-45 sets out the guidance relating to how a reporting entity determines the functional currency of a foreign entity (including of a foreign entity in a highly inflationary economy), re-measures the books of record (if necessary), and characterizes transaction gains and losses. Pursuant to Section 830-10-45, the assets, liabilities, and operations of a foreign entity shall be measured using the functional currency of that entity. An entity’s functional currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the environment, or local currency, in which an entity primarily generates and expends cash.   The functional currency of each foreign subsidiary is determined based on management’s judgment and involves consideration of all relevant economic facts and circumstances affecting the subsidiary. Generally, the currency in which the subsidiary transacts a majority of its transactions, including billings, financing, payroll and other expenditures, would be considered the functional currency, but any dependency upon the parent and the nature of the subsidiary’s operations must also be considered. If a subsidiary’s functional currency is deemed to be the local currency, then any gain or loss associated with the translation of that subsidiary’s financial statements is included in accumulated other comprehensive income. However, if the functional currency is deemed to be the U.S. Dollar, then any gain or loss associated with the re-measurement of these financial statements from the local currency to the functional currency would be included in the condensed consolidated statements of operations and comprehensive income (loss). If the Company disposes of foreign subsidiaries, then any cumulative translation gains or losses would be recorded into the condensed consolidated statements of operations and comprehensive income (loss). If the Company determines that there has been a change in the functional currency of a subsidiary to the U.S. Dollar, any translation gains or losses arising after the date of change would be included within the condensed consolidated statements of operations and comprehensive income (loss).   Based on an assessment of the factors discussed above, the management of the Company determined its subsidiary’s local currency (i.e. the Canadian dollar) to be the functional currency for its foreign subsidiary.

Recent Accounting Pronouncements   Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of March 31, 2021.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Carrying</td> <td> </td> <td> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value Measurement Using</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Value</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 40%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Derivative warrants liabilities</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td></tr> </table>   The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2020.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Carrying</td> <td> </td> <td> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value Measurement Using</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Value</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 1</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 2</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level 3</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 40%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Derivative warrants liabilities</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">83,670</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">83,670</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">83,670</td> <td> </td></tr> </table>

The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2021 and the year ended December 31, 2020:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2"> Fair Value Measurement Using Level 3</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Inputs Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%">Balance, December 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">83,670</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Change in fair value of derivative warrants liabilities</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(83,670</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Balance, March 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The fair value of the derivative feature of the 127,346 and 295,945 warrants issued to the placement agent of the Company’s 2016 private offering (the “2016 Offering”) and to a holder of its debt for debt cancellation in connection with the Merger, respectively on the issuance dates and at the balance sheet dates were calculated using a Black-Scholes option model valued with the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%">Exercise price</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">1.25</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Risk free interest rate</td> <td> </td> <td> </td> <td style="text-align: right">0.09</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">169</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Contractual term</td> <td> </td> <td> </td> <td style="text-align: right">0.14 Years</td> <td> </td></tr> </table>

The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the condensed consolidated statements of operations.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Potentially Outstanding Dilutive Common Shares</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended March 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">For the Three Months Ended March 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Conversion Feature Shares</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Common shares issuable under the conversion feature of preferred shares</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">872,766</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">872,766</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Stock Options</td> <td> </td> <td> </td> <td style="text-align: right">5,673,861</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,925,682</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Warrants</td> <td> </td> <td> </td> <td style="text-align: right">3,483,767</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,826,658</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Convertible Notes</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,598,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">800,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total potentially outstanding dilutive common shares</td> <td> </td> <td> </td> <td style="text-align: right">11,628,394</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9,425,106</td> <td> </td></tr> </table>

Accounts payable and accrued expenses consist of the following at:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">March 31, 2021</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Accounting</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">36,161</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">36,161</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Research and development</td> <td> </td> <td> </td> <td style="text-align: right">381,062</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">393,496</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Other</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">233,745</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">141,860</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">650,968</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">571,517</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">Maturity Date of Notes for Twelve Months Ending March 31, 2021,</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Amount due</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">2022</td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2023</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; text-align: justify">2024</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">1,597,500</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2025</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; text-align: justify">2026</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">100,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: justify">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,697,500</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">Maturity Date of Notes for Twelve Months Ending March 31, 2021,</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Amount due</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify">2022</td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2023</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; text-align: justify">2024</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">400,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify">2025</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; text-align: justify">2026</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt; text-align: justify">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">400,000</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

There were 5,673,861 options outstanding as of March 31, 2021. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%">Exercise price</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">5.60</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Risk free interest rate</td> <td> </td> <td> </td> <td style="text-align: right">0.81%-1.54 %</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected life in years</td> <td> </td> <td> </td> <td style="text-align: right">5-10</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">149%-158 %</td> <td> </td></tr> </table>   There were 5,597,861 options outstanding as of December 31, 2020. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%">Exercise price</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">1.75</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Risk free interest rate</td> <td> </td> <td> </td> <td style="text-align: right">0.64%-1.61 %</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected life in years</td> <td> </td> <td> </td> <td style="text-align: right">10</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">140%-146 %</td> <td> </td></tr> </table>

The following is an analysis of the stock option grant activity under the Plan:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2"> Weighted Average</td> <td> </td> <td> </td> <td colspan="2"> Weighted Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Remaining Life</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%">Stock Options</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding December 31, 2020</td> <td> </td> <td> </td> <td style="text-align: right">5,597,861</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.47</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.48</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Granted</td> <td> </td> <td> </td> <td style="text-align: right">366,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.60</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9.69</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Expired</td> <td> </td> <td> </td> <td style="text-align: right">(280,000</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Exercised</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(10,000</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.00</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Outstanding March 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5,673,861</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1.76</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6.78</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

A summary of the status of the Company’s nonvested options as of March 31, 2021, and changes during the three months ended March 31, 2021, is presented below:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Nonvested Options</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted- Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Nonvested at December 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">862,833</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">1.75</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">366,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.60</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Vested</td> <td> </td> <td> </td> <td style="text-align: right">(106,291</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">4.70</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Forfeited</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Nonvested at March 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,122,542</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2.93</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

NOTE 6 - STOCKHOLDERS’ DEFICIT   Stock-Based Compensation   In connection with the consummation of the Merger completed on February 12, 2016, we adopted Prior Protagenic’s 2006 Employee, Director and Consultant Stock Plan (the “2006 Plan”). On June 17, 2016, our stockholders adopted the 2016 Plan and, as a result, we terminated the 2006 Plan. We will not grant any further awards under the 2006 Plan. All outstanding grants under the 2006 Plan will continue in effect in accordance with the terms of the particular grant and the 2006 Plan.   Pursuant to the 2016 Plan, the Company’s Compensation Committee may grant awards to any employee, officer, director, consultant, advisor or other individual service provider of the Company or any subsidiary. On each of January 1, 2017, January 1, 2019 and January 1, 2020, pursuant to an annual “evergreen” provision contained in the 2016 Plan, the number of shares reserved for future grants was increased by 564,378 shares, or a total of 1,693,134 shares. As a result of these increases, as of March 31, 2021 and December 31, 2020, the aggregate number of shares of common stock available for awards under the 2016 Plan was 4,868,623 shares and 4,868,623 shares, respectively. Options issued under the 2016 Plan are exercisable for up to ten years from the date of issuance.   There were 5,673,861 options outstanding as of March 31, 2021. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%">Exercise price</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">5.60</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Risk free interest rate</td> <td> </td> <td> </td> <td style="text-align: right">0.81%-1.54 %</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected life in years</td> <td> </td> <td> </td> <td style="text-align: right">5-10</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">149%-158 %</td> <td> </td></tr> </table>   There were 5,597,861 options outstanding as of December 31, 2020. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%">Exercise price</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">1.75</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Risk free interest rate</td> <td> </td> <td> </td> <td style="text-align: right">0.64%-1.61 %</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected life in years</td> <td> </td> <td> </td> <td style="text-align: right">10</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">140%-146 %</td> <td> </td></tr> </table>   The following is an analysis of the stock option grant activity under the Plan:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2"> Weighted Average</td> <td> </td> <td> </td> <td colspan="2"> Weighted Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Remaining Life</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%">Stock Options</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding December 31, 2020</td> <td> </td> <td> </td> <td style="text-align: right">5,597,861</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.47</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.48</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Granted</td> <td> </td> <td> </td> <td style="text-align: right">366,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.60</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">9.69</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Expired</td> <td> </td> <td> </td> <td style="text-align: right">(280,000</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">1.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Exercised</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(10,000</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.00</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Outstanding March 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5,673,861</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1.76</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6.78</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   A summary of the status of the Company’s nonvested options as of March 31, 2021, and changes during the three months ended March 31, 2021, is presented below:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Nonvested Options</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted- Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Nonvested at December 31, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">862,833</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 16%; text-align: right">1.75</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">366,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">5.60</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Vested</td> <td> </td> <td> </td> <td style="text-align: right">(106,291</td> <td>)</td> <td> </td> <td>$</td> <td style="text-align: right">4.70</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Forfeited</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Nonvested at March 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,122,542</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2.93</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   As of March 31, 2021, the Company had 5,673,861 shares issuable under options outstanding at a weighted average exercise price of $1.76 and an intrinsic value of $23,025,089.   The total number of options granted during the three months ended March 31, 2021 and 2020 was 366,000 and 1,387,497, respectively. The exercise price for these options was $5.60 per share.   The Company recognized compensation expense related to options issued of $345,975 and $360,436 during the three months ended March 31, 2021 and 2020, respectively, in which $344,499 and $325,794 is included in general and administrative expenses and $1,476 and $34,641 in research and development expenses, respectively. For the three months ended March 31, 2021, $136,203 of the stock compensation was related to employees and $209,772 was related to non-employees.   As of March 31, 2021, the unamortized stock option expense was $2,778,726 with $397,760 being related to employees and $2,380,966 being related to non-employees. As of March 31, 2021, the weighted average period for the unamortized stock compensation to be recognized is 3.50 years.   On February 25, 2021, the Company issued a total of 366,000 options to purchase shares of the Company’s common stock to five individuals, with 350,000 of these options being issued to related parties. These options had a grant date fair value of $2,009,063. These options have an exercise price of $5.60. 16,000 of the options vest immediately and 350,000 of the options vest monthly over 48 months. These options were approved by the board of directors on February 25, 2021.   During the three months ended March 31, 2021, 10,000 options were exercised for 10,000 shares of the Company’s common stock. These options had an exercise price of $1.00.   Warrants:   A summary of warrant issuances are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2"> Weighted Average</td> <td> </td> <td> </td> <td colspan="2"> Weighted Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Remaining Life</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%">Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding December 31, 2020</td> <td> </td> <td> </td> <td style="text-align: right">4,007,058</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.06</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.86</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expired</td> <td> </td> <td> </td> <td style="text-align: right">(150,249</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">1.25</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Exercised</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(373,042</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.25</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Outstanding March 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">3,483,767</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1.03</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1.85</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   As of March 31, 2021, the Company had 3,483,767 shares issuable under warrants outstanding at a weighted average exercise price of $1.03 and an intrinsic value of $16,684,157.   During the three months ended March 31, 2021, 373,042 warrants were exercised for 240,123 shares of the Company’s common stock. The Company received $27,125 from these exercises.

A summary of warrant issuances are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2"> Weighted Average</td> <td> </td> <td> </td> <td colspan="2"> Weighted Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Remaining Life</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%">Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding December 31, 2020</td> <td> </td> <td> </td> <td style="text-align: right">4,007,058</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.06</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.86</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expired</td> <td> </td> <td> </td> <td style="text-align: right">(150,249</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">1.25</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Exercised</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(373,042</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.25</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Outstanding March 31, 2021</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">3,483,767</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1.03</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1.85</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

EX-101.SCH 7 ptix-20210331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Changes In Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Nature of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Liquidity link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Accounts Payable and Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Notes Payable And Convertible Note Payable (PIK Notes) link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Collaborative Agreements link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Accounts Payable and Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Notes Payable And Convertible Note Payable (PIK Notes) (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Stockholders' Deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Accounts Payable and Accrued Expenses (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Notes Payable And Convertible Note Payable (PIK Notes) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Notes Payable And Convertible Note Payable (PIK Notes) - Schedule of Maturity Date of Notes (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Stockholders' Deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Stockholders' Deficit - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Stockholders' Deficit - Schedule of Share-based Compensation, Stock Options, Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Stockholders' Deficit - Schedule of Share-based Compensation Nonvested Shares (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Stockholders' Deficit - Summary of Warrant Issuances (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Collaborative Agreements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 ptix-20210331_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 ptix-20210331_def.xml XBRL DEFINITION FILE EX-101.LAB 10 ptix-20210331_lab.xml XBRL LABEL FILE Counterparty Name [Axis] University of Toronto [Member] Class of Stock [Axis] Series B Convertible Preferred Stock [Member] Range [Axis] Minimum [Member] Maximum [Member] Title of Individual [Axis] Consultant [Member] Debt Instrument [Axis] Unsecured Convertible Notes [Member] Measurement Input Type [Axis] Reported Value Measurement [Member] Fair Value, Hierarchy [Axis] Fair Value, Inputs, Level 1 [Member] Estimate of Fair Value Measurement [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Measurement Input, Exercise Price [Member] Contractual Term [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Toxicology Studies [Member] Unsecured Convertible Notes with Related Parties [Member] Award Type [Axis] Stock Options [Member] Five Individuals [Member] Related Parties [Member] Scenario [Axis] Settlement of Accrued Compensation [Member] Vesting [Axis] Options Vested Over 48 Months [Member] Class of Warrant or Right [Axis] Warrants [Member] Dr. David Lovejoy [Member] Finite-Lived Intangible Assets by Major Class [Axis] Licensing Agreements [Member] Related Party [Member] Measurement Input, Risk Free Interest Rate [Member] Dividend Yield [Member] Expected Volatility [Member] Related Party Transaction [Axis] Options to Related Party [Member] Plan Name [Axis] 2016 Plan [Member] Forecast [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Accumulated Other Comprehensive Loss [Member] Convertible Notes Payable [Member] Convertible Notes Payable - Related Party [Member] Property, Plant and Equipment, Type [Axis] Equipment [Member] Sale of Stock [Axis] Private Placement [Member] Antidilutive Securities [Axis] Conversion Feature Shares [Member] Stock Options [Member] Convertible Notes [Member] Promissory Note [Member] Income Statement Location [Axis] General and Administrative Expense [Member] Research and Development Expenses [Member] Employees [Member] Non-Employees [Member] Research Agreements [Member] 5 Individuals [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Public Offering [Member] 45-day Option [Member] Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] ASSETS CURRENT ASSETS Cash Prepaid expenses TOTAL CURRENT ASSETS TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES Accounts payable and accrued expenses Derivative liability TOTAL CURRENT LIABILITIES Note Payable PIK convertible notes payable, net of debt discount PIK convertible notes payable, net of debt discount - related parties TOTAL LIABILITIES STOCKHOLDERS' DEFICIT Preferred stock, $0.000001 par value; 20,000,000 shares authorized; 872,766 shares issued and outstanding in the following classes: Common stock, $.0001 par value, 100,000,000 shares authorized, 10,610,603 and 10,360,480 shares issued and outstanding at March 31, 2021, and December 31, 2020 Additional paid-in-capital Accumulated deficit Accumulated other comprehensive loss TOTAL STOCKHOLDERS' DEFICIT TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] OPERATING AND ADMINISTRATIVE EXPENSES Research and development General and administrative TOTAL OPERATING AND ADMINISTRATIVE EXPENSES LOSS FROM OPERATIONS OTHER (EXPENSE) INCOME Interest income Interest expense Change in fair value of derivative liability TOTAL OTHER INCOME (EXPENSES) LOSS BEFORE INCOME TAX INCOME TAX EXPENSE NET LOSS COMPREHENSIVE LOSS Other Comprehensive Loss - net of tax Foreign exchange translation gain (loss) TOTAL COMPREHENSIVE LOSS Net loss per common share - Basic and Diluted Weighted average common shares - Basic and Diluted Balance Balance, shares Foreign currency translation loss Stock compensation - stock options Debt discount from beneficial conversion feature Issuance of options for settlement of accrued payroll Modification of warrants Exercise of options Exercise of options, shares Exercise of warrants Exercise of warrants, shares Net loss Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net Loss Adjustments to reconcile net loss to net cash used in operating activities Depreciation expense Stock based compensation Change in fair value of the derivative liability Amortization of debt discount Loss on settlement of accounts payable Changes in operating assets and liabilities Prepaid expenses Accounts payable and accrued expenses NET CASH USED IN OPERATING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Exercise of warrants for cash Proceeds from notes payable Proceeds from convertible notes NET CASH PROVIDED BY FINANCING ACTIVITIES Effect of exchange rate on cash NET DECREASE IN CASH CASH, BEGINNING OF YEAR CASH, END OF YEAR SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Cash paid for interest expense Cash paid for income taxes NONCASH FINANCING AND INVESTING TRANSACTIONS Debt discount from beneficial conversion feature Issuance of options for settlement of accounts payable Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Nature of Business Liquidity Liquidity Accounting Policies [Abstract] Summary of Significant Accounting Policies Payables and Accruals [Abstract] Accounts Payable and Accrued Expenses Debt Disclosure [Abstract] Notes Payable And Convertible Note Payable (PIK Notes) Equity [Abstract] Stockholders' Deficit EX-101.PRE 11 ptix-20210331_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2021	May 14, 2021
Cover [Abstract]
Entity Registrant Name	Protagenic Therapeutics, Inc.\new
Entity Central Index Key	0001022899
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		14,643,780
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
CURRENT ASSETS
Cash	$ 191,674	$ 671,091
Prepaid expenses	4,468	208,156
TOTAL CURRENT ASSETS	196,142	879,247
TOTAL ASSETS	196,142	879,247
CURRENT LIABILITIES
Accounts payable and accrued expenses	650,968	571,517
Derivative liability		83,670
TOTAL CURRENT LIABILITIES	650,968	655,187
Note Payable	100,000
PIK convertible notes payable, net of debt discount	1,126,048	1,081,384
PIK convertible notes payable, net of debt discount - related parties	301,723	292,412
TOTAL LIABILITIES	2,178,739	2,028,983
STOCKHOLDERS' DEFICIT
Common stock, $.0001 par value, 100,000,000 shares authorized, 10,610,603 and 10,360,480 shares issued and outstanding at March 31, 2021, and December 31, 2020	1,061	1,036
Additional paid-in-capital	17,092,824	16,719,749
Accumulated deficit	(18,905,388)	(17,698,936)
Accumulated other comprehensive loss	(171,095)	(171,586)
TOTAL STOCKHOLDERS' DEFICIT	(1,982,597)	(1,149,736)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	196,142	879,247
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, $0.000001 par value; 20,000,000 shares authorized; 872,766 shares issued and outstanding in the following classes:	$ 1	$ 1

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	872,766
Preferred stock, shares outstanding	872,766
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	10,610,603	10,360,480
Common stock, shares outstanding	10,610,603	10,360,480
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	18,000,000	18,000,000
Preferred stock, shares issued	872,766	872,766
Preferred stock, shares outstanding	872,766	872,766

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
OPERATING AND ADMINISTRATIVE EXPENSES
Research and development	$ 592,351	$ 65,959
General and administrative	613,839	454,777
TOTAL OPERATING AND ADMINISTRATIVE EXPENSES	1,206,190	520,736
LOSS FROM OPERATIONS	(1,206,190)	(520,736)
OTHER (EXPENSE) INCOME
Interest income	5	384
Interest expense	(83,937)	(38,986)
Change in fair value of derivative liability	83,670	60,749
TOTAL OTHER INCOME (EXPENSES)	(262)	22,147
LOSS BEFORE INCOME TAX	(1,206,452)	(498,589)
INCOME TAX EXPENSE
NET LOSS	(1,206,452)	(498,589)
Other Comprehensive Loss - net of tax
Foreign exchange translation gain (loss)	491	(2,419)
TOTAL COMPREHENSIVE LOSS	$ (1,205,961)	$ (501,008)
Net loss per common share - Basic and Diluted	$ (0.11)	$ (0.05)
Weighted average common shares - Basic and Diluted	10,520,484	10,261,419

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Changes In Stockholders' Deficit (Unaudited) - USD ($)	Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Total
Balance at Dec. 31, 2019	$ 1	$ 1,026	$ 14,687,172	$ (15,150,201)	$ (172,364)	$ (634,366)
Balance, shares at Dec. 31, 2019	872,766	10,261,419
Foreign currency translation loss					(2,419)	(2,419)
Stock compensation - stock options			360,436			360,436
Debt discount from beneficial conversion feature			89,204			89,204
Issuance of options for settlement of accrued payroll			93,950			93,950
Modification of warrants			5,861			5,861
Net loss				(498,589)		(498,589)
Balance at Mar. 31, 2020	$ 1	$ 1,026	15,236,623	(15,648,790)	(174,783)	(585,923)
Balance, shares at Mar. 31, 2020	872,766	10,261,419
Balance at Dec. 31, 2020	$ 1	$ 1,036	16,719,749	(17,698,936)	(171,586)	(1,149,736)
Balance, shares at Dec. 31, 2020	872,766	10,360,480
Foreign currency translation loss					491	491
Stock compensation - stock options			345,975			345,975
Exercise of options		$ 1	(1)
Exercise of options, shares		10,000				10,000
Exercise of warrants		$ 24	27,101			$ 27,125
Exercise of warrants, shares		240,123
Net loss				(1,206,452)		(1,206,452)
Balance at Mar. 31, 2021	$ 1	$ 1,061	$ 17,092,824	$ (18,905,388)	$ (171,095)	$ (1,982,597)
Balance, shares at Mar. 31, 2021	872,766	10,610,603

XML 17 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$ (1,206,452)	$ (498,589)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense		84
Stock based compensation	345,975	360,436
Change in fair value of the derivative liability	(83,670)	(60,749)
Amortization of debt discount	53,975	27,357
Loss on settlement of accounts payable		5,861
Changes in operating assets and liabilities
Prepaid expenses	203,688	11,669
Accounts payable and accrued expenses	78,777	(210,475)
NET CASH USED IN OPERATING ACTIVITIES	(607,707)	(364,406)
CASH FLOWS FROM FINANCING ACTIVITIES
Exercise of warrants for cash	27,125
Proceeds from notes payable	100,000
Proceeds from convertible notes		330,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	127,125	330,000
Effect of exchange rate on cash	1,165	(10,245)
NET DECREASE IN CASH	(479,417)	(44,651)
CASH, BEGINNING OF YEAR	671,091	753,972
CASH, END OF YEAR	191,674	753,972
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest expense
Cash paid for income taxes
NONCASH FINANCING AND INVESTING TRANSACTIONS
Debt discount from beneficial conversion feature		89,204
Issuance of options for settlement of accounts payable		$ 93,950

XML 18 R7.htm IDEA: XBRL DOCUMENT

Organization and Nature of Business

3 Months Ended

Mar. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Nature of Business

NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS

Company Background

XML 19 R8.htm IDEA: XBRL DOCUMENT

Liquidity

3 Months Ended

Mar. 31, 2021

Liquidity

Liquidity

NOTE 2 - LIQUIDITY

XML 20 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

NOTE 3 - SUMMARY OF SIGNFICANT ACCOUNTING POLICIES

Basis of presentation

Principles of consolidation

Reclassifications:

Reclassifications of prior periods have been made to conform with current year presentation

Use of estimates

Concentrations of Credit Risk

Cash and Cash Equivalents

Fair Value Measurements

The three levels are described below:

Level 1 Inputs – Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company;

Level 2 Inputs – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;

Level 3 Inputs – Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.

Carrying

Fair Value Measurement Using

Value

Level 1

Level 2

Level 3

Total

Derivative warrants liabilities

—

The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2020.

	Carrying		Fair Value Measurement Using
	Value		Level 1		Level 2		Level 3		Total

Derivative warrants liabilities	$	83,670	$	—	$	—	$	83,670	$	83,670

	Fair Value Measurement Using Level 3
	Inputs Total
Balance, December 31, 2020	$	83,670
Change in fair value of derivative warrants liabilities		(83,670	)
Balance, March 31, 2021	$	-

	December 31, 2020
Exercise price		1.25
Risk free interest rate		0.09	%
Dividend yield		0.00	%
Expected volatility		169	%
Contractual term		0.14 Years

Risk-free interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note with a similar expected term on the date of measurement.

Dividend yield: The Company uses a 0% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring dividends in the near future.

Expected term: The Company’s expected term is based on the remaining contractual maturity of the warrants.

Derivative Liability

Stock-Based Compensation

Basic and Diluted Net (Loss) per Common Share

	Potentially Outstanding Dilutive Common Shares
	For the Three Months Ended March 31, 2021		For the Three Months Ended March 31, 2020

Conversion Feature Shares

Common shares issuable under the conversion feature of preferred shares		872,766		872,766

Stock Options		5,673,861		3,925,682

Warrants		3,483,767		3,826,658

Convertible Notes		1,598,000		800,000

Total potentially outstanding dilutive common shares		11,628,394		9,425,106

Research and Development

Research and development expenses are charged to operations as incurred.

Foreign Currency Translation

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Expenses

3 Months Ended

Mar. 31, 2021

Payables and Accruals [Abstract]

Accounts Payable and Accrued Expenses

NOTE 4 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consist of the following at:

	March 31, 2021		December 31, 2020

Accounting	$	36,161	$	36,161
Research and development		381,062		393,496
Other		233,745		141,860

Total	$	650,968	$	571,517

XML 22 R11.htm IDEA: XBRL DOCUMENT

Notes Payable And Convertible Note Payable (PIK Notes)

3 Months Ended

Mar. 31, 2021

Debt Disclosure [Abstract]

Notes Payable And Convertible Note Payable (PIK Notes)

NOTE 5 – NOTE PAYABLE AND CONVERTIBLE NOTE PAYABLE (PIK NOTES)

Note Payable

As of March 31, 2021 and December 31, 2020, the Company owes $100,000 and $0 on the outstanding Note, respectively.

Convertible Notes Payable

As of March 31, 2021 and December 31, 2020, the Company owes $1,597,500 and $1,597,500 on the outstanding Convertible Notes, respectively.

Maturity Date of Notes for Twelve Months Ending March 31, 2021,	Amount due
2022	$	-
2023		-
2024		1,597,500
2025		-
2026		100,000
Total	$	1,697,500

Convertible Notes Payable – Related Parties

As of March 31, 2021 and December 31, 2020, the Company owes $400,000 and $400,000 on the outstanding Convertible Notes, respectively.

Maturity Date of Notes for Twelve Months Ending March 31, 2021,	Amount due
2022	$	-
2023		-
2024		400,000
2025		-
2026		-
Total	$	400,000

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit

3 Months Ended

Mar. 31, 2021

Equity [Abstract]

Stockholders' Deficit

NOTE 6 - STOCKHOLDERS’ DEFICIT

Stock-Based Compensation

There were 5,673,861 options outstanding as of March 31, 2021. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows:

Exercise price	$	5.60
Expected dividend yield		0	%
Risk free interest rate		0.81%-1.54 %
Expected life in years		5-10
Expected volatility		149%-158 %

There were 5,597,861 options outstanding as of December 31, 2020. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows:

Exercise price	$	1.75
Expected dividend yield		0	%
Risk free interest rate		0.64%-1.61 %
Expected life in years		10
Expected volatility		140%-146 %

The following is an analysis of the stock option grant activity under the Plan:

				Weighted Average		Weighted Average
	Number			Exercise Price		Remaining Life
*Stock Options*

Outstanding December 31, 2020		5,597,861		$	1.47		6.48
Granted		366,000		$	5.60		9.69
Expired		(280,000	)	$	1.00		-
Exercised		(10,000	)	$	1.00		-
Outstanding March 31, 2021		5,673,861		$	1.76		6.78

A summary of the status of the Company’s nonvested options as of March 31, 2021, and changes during the three months ended March 31, 2021, is presented below:

Nonvested Options	Options			Weighted- Average Exercise Price
Nonvested at December 31, 2020		862,833		$	1.75
Granted		366,000		$	5.60
Vested		(106,291	)	$	4.70
Forfeited		-		$	-
Nonvested at March 31, 2021		1,122,542		$	2.93

As of March 31, 2021, the Company had 5,673,861 shares issuable under options outstanding at a weighted average exercise price of $1.76 and an intrinsic value of $23,025,089.

The total number of options granted during the three months ended March 31, 2021 and 2020 was 366,000 and 1,387,497, respectively. The exercise price for these options was $5.60 per share.

During the three months ended March 31, 2021, 10,000 options were exercised for 10,000 shares of the Company’s common stock. These options had an exercise price of $1.00.

Warrants:

A summary of warrant issuances are as follows:

				Weighted Average		Weighted Average
	Number			Exercise Price		Remaining Life
*Warrants*

Outstanding December 31, 2020		4,007,058		$	1.06		1.86
Expired		(150,249	)		1.25		-
Exercised		(373,042	)		1.25		-
Outstanding March 31, 2021		3,483,767		$	1.03		1.85

As of March 31, 2021, the Company had 3,483,767 shares issuable under warrants outstanding at a weighted average exercise price of $1.03 and an intrinsic value of $16,684,157.

During the three months ended March 31, 2021, 373,042 warrants were exercised for 240,123 shares of the Company’s common stock. The Company received $27,125 from these exercises.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Collaborative Agreements

3 Months Ended

Mar. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Collaborative Agreements

NOTE 7 - COLLABORATIVE AGREEMENTS

The sponsorship research and development expenses pertaining to the Research Agreements were $0 and $0 for the three months ended March 31, 2021 and 2020, respectively.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Commitments and Contingencies

NOTE 8 - COMMITMENTS AND CONTINGENCIES

Licensing Agreements

Legal Proceedings

XML 26 R15.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

Mar. 31, 2021

Related Party Transactions

NOTE 9 – RELATED PARTY TRANSACTIONS

XML 27 R16.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Mar. 31, 2021

Subsequent Events [Abstract]

Subsequent Events

NOTE 10- SUBSEQUENT EVENTS

Subsequent to the period, the Company issued 360,000 shares of the Company’s common stock for the exercise of 360,000 options. The Company received proceeds of $532,500 from the exercise.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Basis of Presentation

Basis of presentation

Principles of Consolidation

Principles of consolidation

Reclassifications

Reclassifications:

Reclassifications of prior periods have been made to conform with current year presentation

Use of Estimates

Use of estimates

Concentrations of Credit Risk

Concentrations of Credit Risk

Cash and Cash Equivalents

Cash and Cash Equivalents

Fair Value Measurements

Fair Value Measurements

The three levels are described below:

Level 1 Inputs – Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company;

Level 2 Inputs – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;

Level 3 Inputs – Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.

Carrying

Fair Value Measurement Using

Value

Level 1

Level 2

Level 3

Total

Derivative warrants liabilities

—

The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2020.

	Carrying		Fair Value Measurement Using
	Value		Level 1		Level 2		Level 3		Total

Derivative warrants liabilities	$	83,670	$	—	$	—	$	83,670	$	83,670

	Fair Value Measurement Using Level 3
	Inputs Total
Balance, December 31, 2020	$	83,670
Change in fair value of derivative warrants liabilities		(83,670	)
Balance, March 31, 2021	$	-

	December 31, 2020
Exercise price		1.25
Risk free interest rate		0.09	%
Dividend yield		0.00	%
Expected volatility		169	%
Contractual term		0.14 Years

Risk-free interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note with a similar expected term on the date of measurement.

Dividend yield: The Company uses a 0% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring dividends in the near future.

Expected term: The Company’s expected term is based on the remaining contractual maturity of the warrants.

Derivative Liability

Derivative Liability

Stock-Based Compensation

Stock-Based Compensation

Basic and Diluted Net (Loss) Per Common Share

Basic and Diluted Net (Loss) per Common Share

	Potentially Outstanding Dilutive Common Shares
	For the Three Months Ended March 31, 2021		For the Three Months Ended March 31, 2020

Conversion Feature Shares

Common shares issuable under the conversion feature of preferred shares		872,766		872,766

Stock Options		5,673,861		3,925,682

Warrants		3,483,767		3,826,658

Convertible Notes		1,598,000		800,000

Total potentially outstanding dilutive common shares		11,628,394		9,425,106

Research and Development

Research and Development

Research and development expenses are charged to operations as incurred.

Foreign Currency Translation

Foreign Currency Translation

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of March 31, 2021.

Carrying

Fair Value Measurement Using

Value

Level 1

Level 2

Level 3

Total

Derivative warrants liabilities

—

The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2020.

	Carrying		Fair Value Measurement Using
	Value		Level 1		Level 2		Level 3		Total

Derivative warrants liabilities	$	83,670	$	—	$	—	$	83,670	$	83,670

Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

	Fair Value Measurement Using Level 3
	Inputs Total
Balance, December 31, 2020	$	83,670
Change in fair value of derivative warrants liabilities		(83,670	)
Balance, March 31, 2021	$	-

Schedule of Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques

	December 31, 2020
Exercise price		1.25
Risk free interest rate		0.09	%
Dividend yield		0.00	%
Expected volatility		169	%
Contractual term		0.14 Years

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the condensed consolidated statements of operations.

	Potentially Outstanding Dilutive Common Shares
	For the Three Months Ended March 31, 2021		For the Three Months Ended March 31, 2020

Conversion Feature Shares

Common shares issuable under the conversion feature of preferred shares		872,766		872,766

Stock Options		5,673,861		3,925,682

Warrants		3,483,767		3,826,658

Convertible Notes		1,598,000		800,000

Total potentially outstanding dilutive common shares		11,628,394		9,425,106

XML 30 R19.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2021

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following at:

	March 31, 2021		December 31, 2020

Accounting	$	36,161	$	36,161
Research and development		381,062		393,496
Other		233,745		141,860

Total	$	650,968	$	571,517

XML 31 R20.htm IDEA: XBRL DOCUMENT

Notes Payable And Convertible Note Payable (PIK Notes) (Tables)

3 Months Ended

Mar. 31, 2021

Convertible Notes Payable [Member]

Schedule of Maturity Date of Notes

Maturity Date of Notes for Twelve Months Ending March 31, 2021,	Amount due
2022	$	-
2023		-
2024		1,597,500
2025		-
2026		100,000
Total	$	1,697,500

Convertible Notes Payable - Related Party [Member]

Schedule of Maturity Date of Notes

Maturity Date of Notes for Twelve Months Ending March 31, 2021,	Amount due
2022	$	-
2023		-
2024		400,000
2025		-
2026		-
Total	$	400,000

XML 32 R21.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit (Tables)

3 Months Ended

Mar. 31, 2021

Equity [Abstract]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

There were 5,673,861 options outstanding as of March 31, 2021. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows:

Exercise price	$	5.60
Expected dividend yield		0	%
Risk free interest rate		0.81%-1.54 %
Expected life in years		5-10
Expected volatility		149%-158 %

There were 5,597,861 options outstanding as of December 31, 2020. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows:

Exercise price	$	1.75
Expected dividend yield		0	%
Risk free interest rate		0.64%-1.61 %
Expected life in years		10
Expected volatility		140%-146 %

Schedule of Share-based Compensation, Stock Options, Activity

The following is an analysis of the stock option grant activity under the Plan:

				Weighted Average		Weighted Average
	Number			Exercise Price		Remaining Life
*Stock Options*

Outstanding December 31, 2020		5,597,861		$	1.47		6.48
Granted		366,000		$	5.60		9.69
Expired		(280,000	)	$	1.00		-
Exercised		(10,000	)	$	1.00		-
Outstanding March 31, 2021		5,673,861		$	1.76		6.78

Schedule of Share-based Compensation Nonvested Shares

A summary of the status of the Company’s nonvested options as of March 31, 2021, and changes during the three months ended March 31, 2021, is presented below:

Nonvested Options	Options			Weighted- Average Exercise Price
Nonvested at December 31, 2020		862,833		$	1.75
Granted		366,000		$	5.60
Vested		(106,291	)	$	4.70
Forfeited		-		$	-
Nonvested at March 31, 2021		1,122,542		$	2.93

Summary of Warrant Issuances

A summary of warrant issuances are as follows:

				Weighted Average		Weighted Average
	Number			Exercise Price		Remaining Life
*Warrants*

Outstanding December 31, 2020		4,007,058		$	1.06		1.86
Expired		(150,249	)		1.25		-
Exercised		(373,042	)		1.25		-
Outstanding March 31, 2021		3,483,767		$	1.03		1.85

XML 33 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative)	3 Months Ended
	Mar. 31, 2021 USD ($) shares	Mar. 31, 2020 USD ($)	Dec. 31, 2020 USD ($)
Cash equivalents
Derivative, gain (loss) on derivative, net	$ 83,670	$ 60,749
Warrant expiry date	Feb. 21, 2021
Dividend Yield [Member]
Derivative liability measurement input	0.00		0.00
Warrant expiry date	Feb. 21, 2021
Private Placement [Member]
Fair value of derivative feature	$ 127,346
Class of warrant or right, issued \| shares	295,945
Equipment [Member]
Property, plant and equipment, useful life	3 years

XML 34 R23.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Reported Value Measurement [Member]
Derivative warrants liabilities		$ 83,670
Estimate of Fair Value Measurement [Member]
Derivative warrants liabilities		83,670
Estimate of Fair Value Measurement [Member] \| Fair Value, Inputs, Level 1 [Member]
Derivative warrants liabilities
Estimate of Fair Value Measurement [Member] \| Fair Value, Inputs, Level 2 [Member]
Derivative warrants liabilities
Estimate of Fair Value Measurement [Member] \| Fair Value, Inputs, Level 3 [Member]
Derivative warrants liabilities		$ 83,670

XML 35 R24.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)	3 Months Ended
	Mar. 31, 2021 USD ($)
Accounting Policies [Abstract]
Balance at beginning	$ 83,670
Change in fair value of derivative warrants liabilities	(83,670)
Balance at end

XML 36 R25.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques (Details)	12 Months Ended
	Dec. 31, 2020 $ / shares	Mar. 31, 2021
Measurement Input, Exercise Price [Member]
Share price	$ 1.25
Measurement Input, Risk Free Interest Rate [Member]
Derivative liability measurement input	0.09
Dividend Yield [Member]
Derivative liability measurement input	0.00	0.00
Expected Volatility [Member]
Derivative liability measurement input	169
Contractual Term [Member]
Derivative liability measurement input, contractual term	1 month 20 days

XML 37 R26.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Total potentially outstanding dilutive common shares	11,628,394	9,425,106
Conversion Feature Shares [Member]
Total potentially outstanding dilutive common shares	872,766	872,766
Stock Options [Member]
Total potentially outstanding dilutive common shares	5,673,861	3,925,682
Warrants [Member]
Total potentially outstanding dilutive common shares	3,483,767	3,826,658
Convertible Notes [Member]
Total potentially outstanding dilutive common shares	1,598,000	800,000

XML 38 R27.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Expenses (Details Narrative) - USD ($)		3 Months Ended
	Dec. 31, 2020	Mar. 31, 2021	Oct. 02, 2019
Toxicology Studies [Member]
Estimate for study description	On October 1, 2019, the Company entered into an agreement with a consultant for toxicology studies. The consultant quoted a commitment of approximately $988,000 as an estimate for the study. 50% of the total price was paid upon the signing of the agreement, 35% of the total price is to be paid upon completion of the in-life study, and the remaining 15% of the total price is to be paid upon the issuance of the report. If the Company cancels the study the Company will be required to pay a cancelation fee. If the cancelation happens prior to the arrival of the test animals then the Company will need to pay between 20% and 50% of the animal fees depending on when the cancellation happens. If the cancellation occurs after the animals arrive but before the study begins then the Company will be responsible for paying 50% of the protocol price plus a fee of $7,000 per room/week for animal husbandry until the animals can be relocated or disposed of. If the Company cancels the study after it has begun then the Company will need to pay any fees for procured items for the study and any nonrecoverable expenses incurred by the consultant.
Commitment cost paid	$ 174,106	$ 174,106
Balance due amount	$ 319,799	$ 319,799
Consultant [Member]
Estimate commitment amount			$ 988,000

XML 39 R28.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Accounting	$ 36,161	$ 36,161
Research and development	381,062	393,496
Other	233,745	141,860
Total	$ 650,968	$ 571,517

XML 40 R29.htm IDEA: XBRL DOCUMENT

Notes Payable And Convertible Note Payable (PIK Notes) (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 01, 2021	Dec. 31, 2020
Debt amortized debt discount	$ 53,975	$ 27,357
Promissory Note [Member]
Promissory note	$ 100,000		$ 100,000
Debt interest percentage	110.00%		5.00%
Maturity date	Feb. 28, 2026
Debt default interest percentage	7.50%
Fair value of warrants issued	$ 25,000
Promissory Note [Member] \| Maximum [Member]
Promissory note			$ 7,500,000
Unsecured Convertible Notes [Member]
Promissory note	400,000			400,000
Debt amortized debt discount	44,664
Debt unamortized debt discount	471,452			516,116
Convertible notes payable outstanding	1,597,500			1,597,500
Unsecured Convertible Notes with Related Parties [Member]
Debt amortized debt discount	9,311	$ 9,414
Debt unamortized debt discount	$ 98,277			$ 107,588

XML 41 R30.htm IDEA: XBRL DOCUMENT

Notes Payable And Convertible Note Payable (PIK Notes) - Schedule of Maturity Date of Notes (Details)	Mar. 31, 2021 USD ($)
Convertible Notes Payable [Member]
2022
2023
2024	1,597,500
2025
2026	100,000
Total	1,697,500
Convertible Notes Payable - Related Party [Member]
2022
2023
2024	400,000
2025
2026
Total	$ 400,000

- Definition

Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References + Details

XML 42 R31.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit (Details Narrative) - USD ($)						3 Months Ended
Stockholders' Deficit (Details Narrative) - USD ($)	Feb. 25, 2021	Feb. 25, 2020	Jan. 02, 2020	Jan. 02, 2019	Jan. 02, 2017	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Stock options outstanding						5,673,861		5,597,861
Stock options outstanding weighted average exercise price		$ 5.60				$ 1.76
Stock options intrinsic value						$ 23,025,089		$ 38,328
Number of stock options granted						366,000
Stock option weighted average exercise price per share						$ 5.60
Number of stock options vested						106,291
Stock issued during the period exercised						10,000
Class of warrant or right, outstanding						3,483,767		4,007,058
Common Stock [Member]
Stock issued during the period exercised						10,000
Warrants outstanding						240,123
Proceeds from warrants exercised						$ 27,125
Warrants [Member]
Class of warrant or right, outstanding						3,483,767
Class of warrant or right, outstanding, weighted average exercise price						$ 1.03
Class of warrant or right, outstanding, intrinsic value						$ 16,684,157		$ 782,668
Warrants outstanding						373,042
Options to Related Party [Member]
Stock options outstanding						10,000
Stock options outstanding weighted average exercise price						$ 1.00
Stock issued during the period exercised						10,000
Employees [Member]
Compensation expense						$ 136,203
Unamortized stock option expense						397,760
Non-Employees [Member]
Compensation expense						209,772
Unamortized stock option expense						$ 2,380,966
Five Individuals [Member]
Number of stock options granted		366,000
Stock Options [Member]
Number of stock options granted						366,000	1,387,497
Stock option weighted average exercise price per share							$ 5.60
Compensation expense						$ 345,975	$ 360,436
Stock Options [Member] \| Options Vested Over 48 Months [Member]
Number of stock options vested	16,000	350,000
Stock Options [Member] \| Settlement of Accrued Compensation [Member]
Number of stock options granted		2,009,063
Stock option weighted average exercise price per share		$ 5.60
Stock Options [Member] \| Five Individuals [Member]
Number of stock options granted	366,000
Stock Options [Member] \| Related Parties [Member]
Number of stock options granted		350,000
Stock Options [Member] \| General and Administrative Expense [Member]
Compensation expense						344,499	325,794
Stock Options [Member] \| Research and Development Expenses [Member]
Compensation expense						1,476	$ 34,641
Stock Options [Member]
Unamortized stock option expense						$ 2,778,726
2016 Plan [Member]
Number of additional shares grants for issuance			564,378	564,378	564,378
Number of shares available for grant			1,693,134	1,693,134	1,693,134	4,868,623		4,868,623
Share-based payment award, expiration period						10 years

XML 43 R32.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Exercise price	$ 5.60	$ 1.75
Expected dividend yield	0.00%	0.00%
Expected life in years		10 years
Minimum [Member]
Risk free interest rate	0.81%	0.64%
Expected life in years	5 years
Expected volatility	149.00%	140.00%
Maximum [Member]
Risk free interest rate	1.54%	1.61%
Expected life in years	10 years
Expected volatility	158.00%	146.00%

XML 44 R33.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit - Schedule of Share-based Compensation, Stock Options, Activity (Details) - $ / shares		3 Months Ended
	Feb. 25, 2020	Mar. 31, 2021
Equity [Abstract]
Stock Options Outstanding, Beginning		5,597,861
Stock Options, Granted		366,000
Stock Options, Expired		(280,000)
Stock Option, Exercised		(10,000)
Stock Options Outstanding, Ending		5,673,861
Weighted Average Exercisable Price, Stock Options Outstanding, Beginning
Weighted Average Exercisable Price, Stock Options Outstanding, Granted		$ 5.60
Weighted Average Exercisable Price, Stock Options Outstanding, Expired		1.00
Weighted Average Exercisable Price, Stock Options Outstanding, Exercised		1.00
Weighted Average Exercisable Price, Stock Options Outstanding, Ending	$ 5.60	$ 1.76
Weighted Average Remaining Life, Stock Options Outstanding, Beginning		6 years 5 months 23 days
Weighted Average Remaining Life, Stock Options Outstanding, Granted		9 years 8 months 9 days
Weighted Average Remaining Life, Stock Options Outstanding, Ending		6 years 9 months 11 days

XML 45 R34.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit - Schedule of Share-based Compensation Nonvested Shares (Details)	3 Months Ended
	Mar. 31, 2021 $ / shares shares
Equity [Abstract]
Nonvested Options, Beginning Balance \| shares	862,833
Nonvested Options, Granted \| shares	366,000
Nonvested Options, Vested \| shares	(106,291)
Nonvested Options, Forfeited \| shares
Nonvested Options, Ending Balance \| shares	1,122,542
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 1.75
Weighted Average Exercise Price, Granted \| $ / shares	5.60
Weighted Average Exercise Price, Vested \| $ / shares	4.70
Weighted Average Exercise Price, Forfeited \| $ / shares
Weighted Average Exercise Price, Ending Balance \| $ / shares	$ 2.93

XML 46 R35.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit - Summary of Warrant Issuances (Details)	3 Months Ended
	Mar. 31, 2021 $ / shares shares
Equity [Abstract]
Number of Warrants Outstanding, Beginning \| shares	4,007,058
Number of Warrants Outstanding, Expired \| shares	(150,249)
Number of Warrants Outstanding, Exercised \| shares	(373,042)
Number of Warrants Outstanding, Ending \| shares	3,483,767
Number of Warrants Outstanding, Weighted Average Exercise Price, Beginning \| $ / shares	$ 1.06
Number of Warrants Outstanding, Weighted Average Exercise Price, Expired \| $ / shares	1.25
Number of Warrants Outstanding, Weighted Average Exercise Price, Exercised \| $ / shares	1.25
Number of Warrants Outstanding, Weighted Average Exercise Price, Ending \| $ / shares	$ 1.03
Number of Warrants Outstanding, Weighted Average Remaining Life	1 year 10 months 10 days
Number of Warrants Outstanding, Weighted Average Remaining Life	1 year 10 months 6 days

XML 47 R36.htm IDEA: XBRL DOCUMENT

Collaborative Agreements (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
Collaborative Agreements (Details Narrative) - USD ($)	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2015
Number of stock options vested	106,291
Research and development expense	$ 592,351	$ 65,959
Research Agreements [Member]
Research and development expense	$ 0	$ 0
University of Toronto [Member]
Share-based compensation stock options, grants			25,000
Share-based compensation weighted average exercise price			$ 1.00
Share-based payment award, expiration period			10 years
Options expiration date, description			Exercisable over a ten year period which ends on April 1, 2022.
Dr. David Lovejoy [Member] \| Stock Options [Member]
Share-based compensation stock options, grants	553,299
Share-based compensation weighted average exercise price	$ 1.00
Options expiration date, description	These have an exercise price of $1.00, $1.25 or 1.75 and are exercisable over ten or thirteen year periods which end either on March 30, 2021, December 1, 2022, April 15, 2026, March 1, 2027, October 16, 2027 or on February 13, 2030.
Number of stock options vested	431,112
Number of stock options expired	100,000
Dr. David Lovejoy [Member] \| Stock Options [Member] \| Minimum [Member]
Share-based compensation weighted average exercise price	$ 1.25
Share-based payment award, expiration period	10 years
Dr. David Lovejoy [Member] \| Stock Options [Member] \| Maximum [Member]
Share-based compensation weighted average exercise price	$ 1.75
Share-based payment award, expiration period	13 years

XML 48 R37.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Royalty payment on behalf of sub-licensee, percentage	2.50%
Sales revenue
Interest on amounts owed under license agreement, rate	3.00%
Licensing Agreements [Member]
Royalty payment, percentage	2.50%
Up-front sub-license fees, percentage	10.00%

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

XML 49 R38.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - $ / shares		3 Months Ended
	Feb. 25, 2020	Mar. 31, 2021
Number of stock options granted		366,000
Stock options outstanding weighted average exercise price	$ 5.60	$ 1.76
Option term		6 years 5 months 23 days
Minimum [Member]
Option term	5 years
Maximum [Member]
Option term	10 years
5 Individuals [Member]
Number of stock options granted	366,000
Related Party [Member]
Number of stock options granted	350,000

XML 50 R39.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Apr. 29, 2021	Feb. 25, 2020	May 15, 2021	Mar. 31, 2021
Option to purchase shares of common stock				366,000
Forecast [Member]
Proceeds from public offering	$ 11,400,000
Forecast [Member] \| Public Offering [Member]
Stock issued during the period	3,180,000
Warrants to purchase common stock	3,180,000
Forecast [Member] \| Public Offering [Member] \| 45-day Option [Member]
Stock issued during the period	477,000
Warrants to purchase common stock	477,000
Related Party [Member]
Option to purchase shares of common stock		350,000
Subsequent Event [Member]
Stock issued during the period			493,177
Warrants to purchase common stock			695,137
Subsequent Event [Member] \| Common Stock [Member]
Stock issued during the period			360,000
Option to purchase shares of common stock			360,000
Proceeds from option exercised			$ 532,500
Subsequent Event [Member] \| Related Party [Member]
Stock issued during the period			231,277

EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
-8?20$3;8T.P6BP^0"X99K>]9!:G[07+T^);3 ?!WP^ MVQP_*'V_4.J>/-9"FDE46;L^BF-35*RFYJM:,PDM2Z5K:J&H5[%9:T9+4S%F M:Q&G@\$XKBF7T<.\I8N3%MC MZ>*& L@D&@^@PR77QK9'M/U38-PP.+@K-59]X\(R/:66?=>J67.Y M;;1QV/YV03S2_Q)&M5SR@DU5T=1,VBZ.F@D'*$W%UR8BDM9L$FT/(526Y$): M"!*YE%U7<*R[4[CT9=G=M05<+X;ZB$.#OBQ;\'"0YU!6@I=P]9*<44%EP4@; M7$/V?OJ0*0*9[A#R5^I!9@AD]A\A5Y1_W&/ M$,C1[B"IJ3S(,0(Y#@MYK5=4\N>VH1WA,VH;S1SD66.X![F/0.Z'A;SBOQM> M0N+Q< X0G(.P.'E3UU0_N1CE?"4YG$8A/YX6A6H@/WJ0APCD85C(%QI#YO2) MPI7;APN5NH&W\>+13]L#+&\/PF+.P,ZOC*? ",-FXW3JRC,?$]5+8+_D5A7W ME1(ET^83F3(XC5L?#M-*$MPK0M"%TM3-(,CI2K,NT_A\F%&2X$JI:VZ[Y$>[ M)VQA-L-DP5D/$C-*$E@I-ZX2AL:<:IC@W&HJ#6VGC3U"3"=)8)_DS<*PWXV; MBEULWCY?3"%)8(>@^; WKTDPB22!+8)C9CXF)I-\#$Q M"V6A+81A]K?1T'VTT!9",?TAE&$6RD);Z"/,+NW[F)B%LN";:>^O<5]&D8^) M62@+;"%TJ4OV?$S,0EE@"WV\V&WCZ6-B%LJ";[2]6?&^YLP9U?Y>=(99*&LM M%&\_E93PCDM6SN 2!NH+*HJY)NZGV\D9CMS":MD(<0YUU_)*T7+[Y67[U>CD M#U!+ P04 " J?+%20+O#+8N>9V2KQ?/,P>;:^O],;/;[T]9_-MOO MRM?QC\'NI^G.X>A]S :;HCOXN,S2N=1!"D&: M/L@@R-('C2!HE#YH#$'C]$$3")JD#YI"T#1]T R"9NF#YA T3Q\D.B MWDJ@MZ+>2J"WOOQL$^BMJ+<2Z*VHMQ+HK:BW$NBMJ+<2Z*VHMQ+HK:BW$NBM MJ+<2Z&VHMQ'H;:BW$>AMJ+<1Z&TOER4$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z M&^IM!'H;ZFWOU#O$:^G#H^>^QMO(=U(=^W?]X_.WY7T3<1[=<'9P6;_Z!5!+ M P04 " J?+%2_WEJDI\! =& $P %M#;VYT96YT7U1Y<&5S72YX M;6S-F/#+FTH)JY1)MJ D[N;:U\N'6+IA1 MZ5(MB(G1:,Q2W7AJ_-"W&O%L\DRY6E4^>MF$QZ[4S32V5+DX>MH5ME[36!E3 ME:GR89^MF^R'RW#OD(3.KL85I7!"SDP[MSN\&^[ZW-5E;9A3-E?6OJ@Y5 M;%,QY[<5N:1?XD1&G>=E2IE.5W5H29RQI#)7$/FZ2G:B@WYG'TZ8=E=^M7\G MTV<8*N=6&Q2XQXDQP-(#CY""8)"5(Z" M5(["5(X"58Y"58Z"58["58X"5HY"5H%"5H%"5H%"5H%"5H%"5H%"5H%"5H%" M5H%"5H%"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5OF?9/W0>OG7'ZS; M-:E5V1S\6?=78/8%4$L! A0#% @ *7RQ4@=!36*! L0 ! M ( ! &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4 " I?+%2 MSN6(EN\ K @ $0 @ &O 9&]C4')O<',O8V]R92YX M;6Q02P$"% ,4 " I?+%2F5R<(Q & "<)P $P @ '- M 0 >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( "E\L5(X?&J2K , M !,- 8 " @0X( !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ *7RQ4I#) M9@HO P ?PP !@ ("!6A$ 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0#% @ *GRQ4@[M4B8&!@ PQ8 !@ M ("!AQ\ 'AL+W=O'.B/4# #M" M& @(%"*@ >&PO=V]R:W-H965T&UL4$L! M A0#% @ *GRQ4B"ASKG %0 >S\ !@ ("!;2X 'AL M+W=O&UL4$L! A0#% @ *GRQ4NP!<>1X! OPL !D ("! M14D 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ *GRQ4K5ATFD=!P 4Q$ !D ("!T5P 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *GRQ4C^@ZJIT M%@ $$8 !D ("!<&L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *GRQ4J#(-\*. @ T 8 !D M ("!.(L 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ *GRQ4HR49PS6 @ I@H !D ("!RY8 M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M*GRQ4G:*@*\? P NPD !D ("!"J 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *GRQ4L*&0,,R P 8@L !D M ("![+@ 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ *GRQ4G%-&PO=V]R:W-H965T&UL4$L! A0#% @ *GRQ M4J9'\?3' @ T @ !D ("!2LX 'AL+W=O&PO=V]R:W-H965T6J2GP$ !T8 3 M " ;7> !;0V]N=&5N=%]4>7!E&UL4$L%!@ O - "\ P P (7@ $! end XML 52 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 145 285 1 false 53 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://protagenic.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://protagenic.com/role/BalanceSheets Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://protagenic.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://protagenic.com/role/StatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Changes In Stockholders' Deficit (Unaudited) Sheet http://protagenic.com/role/StatementsOfChangesInStockholdersDeficit Consolidated Statements of Changes In Stockholders' Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://protagenic.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Nature of Business Sheet http://protagenic.com/role/OrganizationAndNatureOfBusiness Organization and Nature of Business Notes 7 false false R8.htm 00000008 - Disclosure - Liquidity Sheet http://protagenic.com/role/Liquidity Liquidity Notes 8 false false R9.htm 00000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://protagenic.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://protagenic.com/role/AccountsPayableAndAccruedExpenses Accounts Payable and Accrued Expenses Notes 10 false false R11.htm 00000011 - Disclosure - Notes Payable And Convertible Note Payable (PIK Notes) Notes http://protagenic.com/role/NotesPayableAndConvertibleNotePayablePikNotes Notes Payable And Convertible Note Payable (PIK Notes) Notes 11 false false R12.htm 00000012 - Disclosure - Stockholders' Deficit Sheet http://protagenic.com/role/StockholdersDeficit Stockholders' Deficit Notes 12 false false R13.htm 00000013 - Disclosure - Collaborative Agreements Sheet http://protagenic.com/role/CollaborativeAgreements Collaborative Agreements Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and Contingencies Sheet http://protagenic.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Related Party Transactions Sheet http://protagenic.com/role/RelatedPartyTransactions Related Party Transactions Notes 15 false false R16.htm 00000016 - Disclosure - Subsequent Events Sheet http://protagenic.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 00000017 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://protagenic.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://protagenic.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Accounts Payable and Accrued Expenses (Tables) Sheet http://protagenic.com/role/AccountsPayableAndAccruedExpensesTables Accounts Payable and Accrued Expenses (Tables) Tables http://protagenic.com/role/AccountsPayableAndAccruedExpenses 19 false false R20.htm 00000020 - Disclosure - Notes Payable And Convertible Note Payable (PIK Notes) (Tables) Notes http://protagenic.com/role/NotesPayableAndConvertibleNotePayablePikNotesTables Notes Payable And Convertible Note Payable (PIK Notes) (Tables) Tables http://protagenic.com/role/NotesPayableAndConvertibleNotePayablePikNotes 20 false false R21.htm 00000021 - Disclosure - Stockholders' Deficit (Tables) Sheet http://protagenic.com/role/StockholdersDeficitTables Stockholders' Deficit (Tables) Tables http://protagenic.com/role/StockholdersDeficit 21 false false R22.htm 00000022 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://protagenic.com/role/SummaryOfSignificantAccountingPoliciesTables 22 false false R23.htm 00000023 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Sheet http://protagenic.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails Summary of Significant Accounting Policies - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Details 23 false false R24.htm 00000024 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) Sheet http://protagenic.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationDetails Summary of Significant Accounting Policies - Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) Details 24 false false R25.htm 00000025 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques (Details) Sheet http://protagenic.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfFairValueMeasurementsRecurringAndNonrecurringValuationTechniquesDetails Summary of Significant Accounting Policies - Schedule of Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques (Details) Details 25 false false R26.htm 00000026 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://protagenic.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 26 false false R27.htm 00000027 - Disclosure - Accounts Payable and Accrued Expenses (Details Narrative) Sheet http://protagenic.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative Accounts Payable and Accrued Expenses (Details Narrative) Details http://protagenic.com/role/AccountsPayableAndAccruedExpensesTables 27 false false R28.htm 00000028 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) Sheet http://protagenic.com/role/AccountsPayableAndAccruedExpenses-ScheduleOfAccountsPayableAndAccruedExpensesDetails Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) Details 28 false false R29.htm 00000029 - Disclosure - Notes Payable And Convertible Note Payable (PIK Notes) (Details Narrative) Notes http://protagenic.com/role/NotesPayableAndConvertibleNotePayablePikNotesDetailsNarrative Notes Payable And Convertible Note Payable (PIK Notes) (Details Narrative) Details http://protagenic.com/role/NotesPayableAndConvertibleNotePayablePikNotesTables 29 false false R30.htm 00000030 - Disclosure - Notes Payable And Convertible Note Payable (PIK Notes) - Schedule of Maturity Date of Notes (Details) Notes http://protagenic.com/role/NotesPayableAndConvertibleNotePayablePikNotes-ScheduleOfMaturityDateOfNotesDetails Notes Payable And Convertible Note Payable (PIK Notes) - Schedule of Maturity Date of Notes (Details) Details http://protagenic.com/role/NotesPayableAndConvertibleNotePayablePikNotesTables 30 false false R31.htm 00000031 - Disclosure - Stockholders' Deficit (Details Narrative) Sheet http://protagenic.com/role/StockholdersDeficitDetailsNarrative Stockholders' Deficit (Details Narrative) Details http://protagenic.com/role/StockholdersDeficitTables 31 false false R32.htm 00000032 - Disclosure - Stockholders' Deficit - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) Sheet http://protagenic.com/role/StockholdersDeficit-ScheduleOfShare-basedPaymentAwardStockOptionsValuationAssumptionsDetails Stockholders' Deficit - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) Details 32 false false R33.htm 00000033 - Disclosure - Stockholders' Deficit - Schedule of Share-based Compensation, Stock Options, Activity (Details) Sheet http://protagenic.com/role/StockholdersDeficit-ScheduleOfShare-basedCompensationStockOptionsActivityDetails Stockholders' Deficit - Schedule of Share-based Compensation, Stock Options, Activity (Details) Details 33 false false R34.htm 00000034 - Disclosure - Stockholders' Deficit - Schedule of Share-based Compensation Nonvested Shares (Details) Sheet http://protagenic.com/role/StockholdersDeficit-ScheduleOfShare-basedCompensationNonvestedSharesDetails Stockholders' Deficit - Schedule of Share-based Compensation Nonvested Shares (Details) Details 34 false false R35.htm 00000035 - Disclosure - Stockholders' Deficit - Summary of Warrant Issuances (Details) Sheet http://protagenic.com/role/StockholdersDeficit-SummaryOfWarrantIssuancesDetails Stockholders' Deficit - Summary of Warrant Issuances (Details) Details 35 false false R36.htm 00000036 - Disclosure - Collaborative Agreements (Details Narrative) Sheet http://protagenic.com/role/CollaborativeAgreementsDetailsNarrative Collaborative Agreements (Details Narrative) Details http://protagenic.com/role/CollaborativeAgreements 36 false false R37.htm 00000037 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://protagenic.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://protagenic.com/role/CommitmentsAndContingencies 37 false false R38.htm 00000038 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://protagenic.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://protagenic.com/role/RelatedPartyTransactions 38 false false R39.htm 00000039 - Disclosure - Subsequent Events (Details Narrative) Sheet http://protagenic.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://protagenic.com/role/SubsequentEvents 39 false false All Reports Book All Reports ptix-20210331.xml ptix-20210331.xsd ptix-20210331_cal.xml ptix-20210331_def.xml ptix-20210331_lab.xml ptix-20210331_pre.xml http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 true true ZIP 56 0001493152-21-011799-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-011799-xbrl.zip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end